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1. Introduction 
 
Neuronal dysfunction and death are hallmarks of acute and chronic 
neurodegenerative diseases such as cerebral ischemia, traumatic brain injury and 
Alzheimer´s disease, respectively. Since afflicted patients suffer from severe and 
often irreversible disability, the personal and economical burden of these disorders is 
immense (1). Despite of this huge socio-economic impact, treatment options 
targeting pathological mechanisms of acute brain injury or progressive 
neurodegenerative diseases remain poorly evolved.  
For instance, the most widely practiced treatment for traumatic brain injury today is 
still decompressive craniectomy (2; 3). This ancient approach dating back to 4000 
BC epitomises the lack of innovative, broadly applicable, and well tolerated treatment 
options in the field of acute brain injuries (2). Consequently, research on the 
underlying mechanisms of neuronal cell death is imperative to overcome this shortfall 
and define reliable and efficient treatment paradigms.  
 
1.1.  Apoptosis 
 
According to current classification, neuronal cell death is executed by three major 
pathways, namely autophagy, apoptosis and necrosis (4-6). The severity and 
duration as well as the nature of the death stimulus determines which cell death 
pathway is initiated. The term apoptosis originally has been introduced by Kerr et al. 
(1972) to describe a morphological phenotype of dying cells, which manifests in 
rounding-up of the cells, reduction of cellular and nuclear volume (pyknosis), nuclear 
fragmentation and plasma membrane blebbing (4; 7). Especially the latter 
characteristic renders apoptosis a favourable form of cell death in development and 
under physiological conditions, when preservation of surrounding cells is desired. 
This is the case with apoptosis, since apoptotic cells do not completely disintegrate in 
the terminal stages of cell death, but rather form apoptotic bodies (remnants of 
membrane blebbing), which are engulfed by neighbouring cells and thus removed by 
phagocytosis. The “discrete” removal of apoptotic bodies by the surrounding tissue 
stands in sharp contrast to effects provoked by cells undergoing necrosis, which 
literally burst and spill their intracellular content into the interstitial space, causing 
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severe inflammatory responses and damage to the surrounding tissue (4). 
Consequently, apoptosis plays an important physiological role in proliferating and 
developing tissue, as it regulates the replacement of senescent or excessive cells 
without causing necrosis, subsequent inflammation and scar formation (8). Further, in 
non-proliferating tissue like the brain, apoptosis has been shown to be of relevance 
during development by controlling synapses and removing excessive and unneeded 
neural cells (9).  
A more detrimental role of apoptosis in neurons, however, is commonly associated 
with pathophysiological conditions like e.g. cerebral ischemia or Parkinson´s disease, 
where apoptotic signaling significantly promotes the progressive and irreversible loss 
of neuronal cells (10). Consequently, apoptosis is significantly involved in neuronal 
cell death in numerous neurological diseases.  
 
1.2. Intrinsic and extrinsic apoptosis 
 
Apoptosis can follow two distinct pathways, namely the intrinsic and the extrinsic 
pathway. These signaling modes, however, share a common final route since both 
ultimately cause the activation of the major effector-caspases, caspase-3, caspase-6 
and caspase-7.  
Caspases are cysteine proteases, which are sequestered in the cytosol under 
physiologic conditions as inactive precursors (11). Activation is effected by 
(auto)proteolysis mediated by initiating caspases and other proteases. Two families 
of caspases can be differentiated, the initiator caspases and the executing caspases. 
The latter group of caspases cleaves various pivotal downstream targets causing e.g. 
disruption of the nuclear envelope and DNA fragmentation which ultimately leads to 
cell death (11; 12).  
The extrinsic pathway is triggered by death receptor stimulation by e.g. Fas-Ligand 
(FasL), Tumor Necrosis Factor α (TNF-α) or Tumor Necrosis Factor Related 
Apoptosis Inducing Ligand (TRAIL) (11; 13). Death receptor stimulation subsequently 
results in oligomerization and recruitment of adaptor proteins, such as Fas-
associated death domain (FADD) and several molecules of caspase-8. This multi-
protein complex is commonly referred to as the death-inducing signaling complex 
(DISC) (12). Autoactivation of caspase-8 at DISC initiates proteolytic activation of 
downstream caspases like caspase-3, -6 and -7. These activated caspases then 
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cause destabilization of the cytoskeleton, fragmentation of the nuclear envelope, 
chromatin condensation and DNA fragmentation. The latter events are mediated by 
caspase-activated deoxyribunuclease (CAD), which is released from the inhibitory 
ligand ICAD by the activated caspase-3 (12) (Figure 1). CAD then causes DNA-
cleavage, a major hallmark of apoptosis, which often is referred to as the “DNA-
ladder”. This term is derived from the fact, that agarose gel electrophoresis of 
genomic DNA from apoptotic cells shows a “ladder-like” pattern of truncated DNA 
fragments. 
 
The upstream caspase-8 interconnects the extrinsic and intrinsic pathway, as it 
activates pro-apoptotic Bcl-2-proteins like Bid, which then set off the cascade of 
intrinsic apoptosis that is characterized by mitochondrial damage. Therefore, Bcl-2 
family proteins have a significant impact on intrinsic apoptosis signaling and cell 
death in general. Bcl-2 proteins can be divided into three groups depending on their 
shared Bcl-2 homology domains (BH1-4).  
The prosurvival members such as Bcl-2, Bcl-XL, and Mcl-1 contain BH domains 1–4, 
whereas BAX and BAK contain BH domains 1–3 and belong to a group of 
proapoptotic effectors, which cause mitochondrial outer membrane permeabilization 
(MOMP) during apoptosis. The third group encompasses proapoptotic members, like 
Bid, Bim and Bad, which contain only the BH3 domain and serve to couple upstream 
stress stimuli to downstream modulation of the multi-BH domain members (14). The 
intrinsic route of apoptosis has closely been linked to mitochondria for execution of 
cell death, relying on the proapoptotic proteins BAK and BAX. In unstressed cells 
BAX is sequestered in the cytosol, while BAK is integrated into the mitochondrial 
membrane.  
Several BH-3 proteins including tBid, Bim and PUMA (p53 up-regulated modulator of 
apoptosis) have been shown to induce a translocation of BAX to the mitochondria in 
response to various stimuli including genomic or metabolic stress (15; 16). Upon 
mitochondrial translocation, BAX undergoes pronounced conformational changes 
forming oligomers with additional BAX or BAK molecules. These oligomers then 
cause the formation of a transmembrane pore in the mitochondrial membrane, which 
leads to subsequent release of further proapoptotic factors from the mitochondria 
(14). The antiapoptotic proteins Bcl-XL and Bcl-2 can sequester BAX and BAK and 
thereby prevent pore formation (15). Different studies suggested, that Bcl-XL and Bcl-
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2 rather sequester activated proapoptotic BH-3 proteins and thus prevent BAX-BAK 
dependent pore formation only indirectly (14). Yet another proapoptotic factor, the 
BH3 only protein BAD has been shown to sequester Bcl-2 and Bcl-XL and thereby 
prevent these from exerting their anti-apoptotic function (14).  
These mechanisms have given rise to the development of Bcl-XL and Bcl-2 inhibitors, 
currently under clinical investigation for the treatment of lymphomas, which sensitize 
cells to cell death by mimicking the BH3 molecule BAD (17; 18). 
Once BAX dependent pore formation occurs at the mitochondria, the proapoptotic 
factors, cytochrome c (Cytc), apoptosis-inducing factor (AIF), Omi/HtrA2 and second 
mitochondria-derived activator of caspase (Smac/DIABLO) are released (11; 12). 
Cytochrome c interacts in the cytosol with APAF-1 to form the apoptosome, a 
complex, which activates caspase 9 and thereby propagates further caspase 
activation and subsequent cell death (Figure 1).  
 
Next to the established role of caspase dependent apoptosis, emerging evidence 
suggests, that AIF release from mitochondria is a detrimental process within 
programmed cell death. Interestingly, in certain tissues, AIF dependent cell death is 
far more important than the established caspase dependent apoptosis. This is 
especially true for neurons and cell death in the adult brain (19; 20). Under 
physiological conditions the flavoprotein AIF is bound in the intermembrane space of 
mitochondria, functioning as an important redox-active enzyme (NADH oxidase). AIF 
release from the mitochondria and AIF mediated induction of cell death has been 
observed in response to various stimuli including excitotoxicity, ischemia or DNA 
alkylating agents (21-23).  
Upon release from mitochondria, AIF translocates to the nucleus and forms an active 
nuclease complex with cyclophilin A (CYPA) to promote DNA degradation and cell 
death (24) (Figure 1). With the discovery of the AIF variant, AIF2, another putative 
mechanism of AIF isoforms has been found, involving ROS generation at the 
mitochondria (25).  
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Figure 1: Apoptotic pathways. Extrinsic pathway (left part): Cell death is triggered by activation of 
death receptors (TNFR1, FasR) inducing the binding of Fas associated death domain (FADD) and/or 
(TRADD). Pro-caspase-8 is recruited to the complex and (auto)activated, followed by a caspase-8 
mediated activation of the effector caspase-3. Caspase-3 in turn cleaves the inhibitor of caspase 
activated deoxyribonuclease (ICAD) thereby releasing the caspase activated deoxyribonuclease 
(CAD), which causes DNA cleavage. Alternatively, caspase-8 can cleave the proapoptotic protein Bid, 
which activates the intrinsic pathway of apoptosis that involves damage to mitochondria (right part). 
The cleaved Bid protein (tBid), increased calcium-levels or ROS in turn can trigger mitochondrial 
membrane permeabilization, which causes the release of mitochondrial proteins like cytochrome c 
(Cytc), Omi/HtrA2, Smac/DIABLO or AIF. Cytochrome c forms a complex with Apaf-1 and pro-
caspase-9, called the apoptosome, which enables the auto-activation of caspase 9. The apoptosome 
then triggers caspase-3 and subsequently CAD. AIF is released from mitochondria and translocates to 
the nucleus where it induces DNA fragmentation. The mitochondrial proteins Omi/HtrA2 and 
Smac/DIABLO induce cytotoxicity by sequestering endogenous inhibitors of caspases thus enhancing 
the caspase response. 
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1.3. p53 dependent apoptosis 
 
The tumor suppressor p53 plays a central role in assuring genomic stability in 
mammalian cells. Activation of p53 in response to DNA damage therefore can induce 
either cell cycle arrest and DNA repair, or apoptosis, depending on the severity of the 
insult. To evoke both effects, p53 regulates the transcription of a wide set of target 
genes, ranging from p21 to induce DNA repair and e.g. BAX and BAK for induction of 
cell death (26-28). 
Upregulation and induction of p53 has been reported in response to various stimuli 
including NMDA receptor mediated excitotoxicity, reactive oxygen species (ROS), 
alkylating agents, hypoxia, β-Amyloid toxicity and 1-methyl-4-phenyl-1,2,3,6- 
tetrahydropyridine (MPTP) (28; 29). Despite this vast range of insults, the underlying 
trigger for p53 stimulation likely lies in the generation of intermediate ROS species 
such as superoxide anions (⋅O2-) and hydroxyl radicals (•OH) which target the 
genomic DNA (30).  
Such oxidative DNA damage includes chemical lesions like hydroxyl radical-modified 
bases (8-hydroxyl-20-deoxyguanosine) and DNA strand breaks (28). p53 activation is 
accompanied by certain modifications of p53 including acetylation, phosphorylation 
and poly(ADP) ribosylation, which serve to prolong the half life of p53 and/or 
enhance its DNA-binding affinity. These modifications are mediated by kinases, 
which function as the actual sensors of DNA damage and transduce the DNA-
damage signal to p53 by the aforementioned modifications. Among these kinases are 
ataxia telangiectasia mutated (ATM), ATM-related protein (ATR) and cell cycle 
regulating kinases CDK4/6 (28; 31). p53-mediated apoptosis is mostly dependent on 
transcription, even though alternative transcription-independent functions of p53 have 
been reported (26; 29).  
The major transcriptional targets of p53 for induction of cell death involve the multi-
domain Bcl-2 family member BAX and the BH3-only proteins Bid, PUMA and Noxa, 
among many others. Furthermore, p53 may promote apoptosis by transcriptional 
repression of anti-apoptotic signaling pathways including CREB (Cyclic AMP 
response element binding protein) and Nuclear factor-kB (NF-κB) (32). 
Consequently, p53 activation reduces the expression of antiapoptotic factors under 
transcriptional control by these pathways, such as Bcl-2, the insulin-like growth factor 
(IGF) receptor, Manganese superoxide reductase (MnSOD), or X-linked inhibitor of 
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apoptosis protein (XIAP) (33). The competetive binding of both NF-κB and p53 to 
p300/CBP (CREB binding protein) has been suggested as the molecular link of this 
reciprocal inhibition (34-37) since p300/CBP is a crucial co-transcription factor 
required by both pathways for proper transcriptional function (Figure 2). In summary, 
p53 possesses a strong apoptotic potential, for which reason inhibition thereof has 
been established as a promising approach to tackle neuronal cell death.  
 
 
Figure 2: Reciprocal repression of p53 and NF-κB through competitive binding of p300 
(modified from Culmsee et al., 2005).  When the transcription factor p53 is activated in response to 
various stress stimuli, it translocates to the nucleus and induces transcription of its various pro-
apoptotic target proteins like Bid, BAX or Fas. Activation of NF-κB, in contrast, mediates survival 
through enhanced transcription of anti-apoptotic proteins such as Bcl-2, Bcl-XL or MnSOD. For 
effective binding to the promoter both transcription factors further require co-factors such as 
p300/CBP. Since, both, p53 and NF-κB compete for the limited pool of p300, blocking p53 by pifithrin-
α may indirectly support NF-κB signaling and thereby further enhance neuroprotection. 
 
1.4. The NF-κB pathway and its implication in neurons 
 
As mentioned in the previous section, certain pathways ensure neuronal survival 
under physiological conditions by antagonizing the various intracellular pro-death 
effectors. Among these, the NF-κB pathway has been identified as a crucial player in 
different cell types, including cancer cells and neurons. While the strong anti-
apoptotic effect of NF-κB mediates unwanted chemoresistance in cancer cells, this 
same pathway has been associated with a desirable increase in survival in neurons 
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(38; 39). The role of NF-κB within the central nervous system, however, is very 
complex and a matter of ongoing debate. Consequently, NF-κB has not only been 
linked to increased survival, but also to enhanced neuronal damage (33; 37; 40-42). 
Even though several possible explanations have been offered, this apparent 
contradiction has not been resolved completely, yet. Evidence established by some 
groups working on NF-κB in cerebral ischemia suggests for instance that the duration 
of ischemia determines the mode of NF-κB response and the final outcome. In this 
respect, a short duration of ischemia below the threshold of cell death was found to 
upregulate NF-κB and to protect against a later more severe insult (preconditioning). 
A strong prolonged ischemia, however, was associated with enhanced NF-κB activity 
and cell death (43).  
Furthermore, a cell-type specific effect of NF-κB is very likely to contribute to the 
convoluted global effect within the CNS. For instance, activation of NF-κB in 
microglial cells has been linked to the release of neurotoxins, which overcomes the 
protection mediated by NF-κB in neurons and thus ultimately promotes cell death 
(44). The abundance of different NF-κB subunits and possible dimer composition 
suggests, that NF-κB can evoke different responses depending on the respective 
dimers. Therefore, the analysis of NF-κB in the CNS requires a detailed investigation 
of NF-κB taking into account the respective subunit and cell types.  
 
The NF-κB pathway consists of 5 transcription factors, which all share a highly 
conserved DNA-binding/dimerization domain called the Rel homology domain (RHD). 
A subset of the NF-κB subunits, namely RelA, RelB and cRel further contains a C-
terminal transactivation domain, which enables them to activate transcription. This 
domain is missing in the p50 and p52 subunits. In order to induce transcription, NF-
κB subunits need to dimerize and translocate from their predominant cytosolic 
location to the nucleus (45).  
For successful transcriptional activation, the dimer must contain at least one factor 
with a transactivation domain; otherwise it can only halt transcription upon DNA 
binding. An exception to this rule is the binding of the auxiliary NF-κB protein Bcl-3 to 
p50/p52 dimers, which then can actively initiate transcription, even though Bcl-3 per 
se does not function as a transcription factor (46).  
A huge variety of stimuli has been reported to activate NF-κB-transcription, including 
proinflammatory cytokines such as TNF-α and interleukin (IL)-1 as well as microbial 
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pathogens (47). Additionally, in neurons NMDA receptor stimulation as well as 
stimulation of metabotropic glutamate receptors has been shown to induce NF-κB 
(48; 49). Further, intracellular stimuli leading to NF-κB activity include oxidative 
stress, genomic stress by chemotherapeutics and hypoxia. 
 
Activation of NF-κB commonly occurs via two main pathways, the canonical and non-
canonical pathway. In their inactive state, RelB, RelA and cRel are sequestered in 
the cytosol by IκB, while p50 and p52 are retained as precursor proteins p105 and 
p100 (45).  
In the canonical pathway the β subunit of the IκB kinase (IKKβ) is activated which 
then phosphorylates the IκB-protein. The ubiquitin ligase machinery in turn, 
recognizes the phosphorylated IκB-proteins and attaches poly-ubiquitin chains, 
linked via lysine-48. These ubiquitin moieties then are recognized by the proteasome, 
resulting in IκB degradation (Figure 3).  
Consequently, activation of the canonical NF-κB pathway can be evaluated by 
increased phosphorylation of IκB, a decreased pool of IκB, and a subsequent nuclear 
translocation of NF-κB dimers (Figure 3 left part).  
In the non-canonical pathway, IκB-α kinase (IKKα) causes phosphorylation of either 
precursor subunit p105 or p100, which then likewise are ubiquitinated and 
recognized by the proteasome. In this case, however, they are not completely 
degraded, but processed, liberating p50 from its precursor p100 and p52 from p105 
(Figure 3 right part). These subunits now translocate to the nucleus.  
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Figure 3: Activation of NF-κB by the canonical and non-canonical pathway. Key elements of the 
canonical NF-κB pathway include members of the IkB (inhibitor of kB) family and the IkB kinase (IKK) 
complex that consists of IKKα–IKKβ heterodimers and the regulatory protein IKKγ/NEMO. Several 
stimuli are known to activate NF-κB, such as the cytokines TNF-α, or an increase in intracellular Ca2+ 
levels, leading to the phosphorylation of the IkB protein. This phosphorylation causes IkB 
polyubiquitination and its subsequent degradation by the proteasome. The NF-κB proteins are thus 
liberated from IkB and translocate to the nucleus, where they can alter gene expression upon binding 
to the promoter within the NF-κB response element. The non-canonical pathway is activated by the 
IkB kinase-α (IKK-α), which stimulates phosphorylation of p100 to induce its processing to p52. IKKα-
induced processing of p100 can stimulate for example the nuclear translocation of the RelB–p52 
dimers. 
 
1.5. Regulation of NF-κB - The role of ubiquitination 
 
Regulation of NF-κB occurs at various levels involving acetylation, phosphorylation 
and ubiquitination of its various signaling proteins. In addition to the aforementioned 
role of phosphorylation for the initiation of NF-κB by IKK kinases, modifications have 
also been reported for active NF-κB transcription factors. In this respect, 
phosphorylation of NF-κB subunits by nuclear kinases, and modification of these 
subunits by acetylases and phosphatases, can result in transcriptional activation and 
repression as well as promoter-specific effects (50). The role of ubiquitin in NF-κB 
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regulation traditionally has been linked to lysine-48 (K48) bound polyubiquitin chains, 
which are attached to certain substrate proteins, marking them for proteasomal 
degradation. The most prominent example is the degradation of IκB during activation 
of the canonical pathway.  
 
More recently, this view on ubiquitination was expanded further, identifying lysine-63 
(K63) bound ubiquitin chains as an important mediator of non-degradative processes, 
such as protein trafficking and signal transduction (51). Further, linear ubiquitin 
chains, linked via alternative amino-acids have been discovered, although their 
physiological role has not been fully understood (52; 53). K63 linked ubiquitination 
has been found on several crucial NF-κB related proteins including Nemo (IKKγ), 
RIP1 and TNF receptor-associated factor 2  (TRAF2). IKKγ has been described as a 
crucial regulatory component of the IKK-complex and ubiquitination of IKKγ has been 
discovered as a prerequisite for proper IKK activation and signal transduction. The 
K63-linked ubiquitin chains seem to facilitate protein–protein interactions in the 
assembly of the IKK signaling complex in response to its upstream kinase TGF-β-
activated kinase 1 (TAK1) (51).  
In addition, TRAF2 and RIP1 are of great importance in TNF-α induced NF-κB 
activation acting upstream of IKKs and TAK1. Similarly, ubiquitination of these is 
required to allow effective signal transduction in response to TNF-α (54-56). 
Furthermore, the auxiliary protein Bcl-3 can be activated upon ubiquitination by the 
E3 ligase Snail, allowing its nuclear translocation. Transfer of ubiquitin residues to 
RIP1 and Nemo is mediated by the ubiquitin ligases cIAP1 and cIAP2 (Cellular 
inhibitor of apoptosis protein-1), while TRAF 2 is ubiquitinated by the ligase Ubc13 
(57).  
In the light of these manifold ubiquitinations required for signal transduction, 
deubiquitination of these components emerges as an effective means of negative 
NF-κB regulation. In line with this notion the deubiquitinating enzymes CYLD and 
A20 have been identified as major negative regulators of the NF-κB pathway. 
 
 
 
1 Introduction 
 
12 
1.6. The tumor suppressor cylindromatosis (CYLD) 
 
Cylindromatosis, CYLD, originally was identified in a rare inherited benign tumor of 
the skin, predominantly affecting the light exposed skin of the face and scalp (58). 
Patients suffering from this disease, termed cylindromatosis as well, carry 
heterozygous germ-line mutations in the CYLD gene lacking a catalytically functional 
deubiquitinating (DUB) domain (59). As mentioned in the previous section, CYLD 
negatively regulates the NF-κB pathway by removing lysine-63 linked poly-ubiquitin 
chains from its various target proteins (60). Among these, RIP1, TRAF2, Nemo 
(IKKγ) and Bcl-3 are the major targets of CYLD.  
In 2006 Massoumi et al. established a possible link between tumor formation in 
CYLD deficient mice and NF-κB activity. In ceratinocytes exposed to UV-light or 12-
O-tetra-decanoylphorbol-13 acetate (TPA) they found that in the absence of CYLD, 
polyubiquitinated Bcl-3 bound to p50/p52 and translocated to the nucleus. As a 
result, CyclinD1 levels were upregulated thereby promoting cell cycle progression, 
proliferation and subsequent tumor formation.  
A higher susceptibility to tumor formation in CYLD deficient animals has also been 
found in a model system of colonic inflammation, showing a dramatic increase in the 
incidence of colitis-associated cancer (61).  
A further role of CYLD, that is also likely linked to its role in NF-κB signaling, has 
been found in the regulation of immune responses to host infections. When exposed 
to streptococcus pneumoniae and haemophilus influenzae, CYLD KO mice 
experienced significantly less severe episodes of pneumonia (62).  
Apart from its regulatory function in the NF-κB pathway, CYLD also controls the c-
Jun kinase (JNK) signaling pathway, a mitogen-activated protein kinase (MAPK) 
pathway, which is involved in several processes including proliferation, differentiation 
and apoptosis.  
A further pivotal role of CYLD has emerged lately, when CYLD was recognized as a 
major signaling molecule within a form of necrotic cell death, termed necroptosis 
(63). This function is described in further detail in the following section. 
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1.7. Necroptosis – an ordered form of necrotic cell death 
 
As opposed to apoptotic and autophagic cell death, necrosis traditionally was 
considered as an exclusively unregulated form of cell death happening in a passive 
manner. Necrosis is characterized by swelling of the endoplasmic reticulum, the 
mitochondria and the cytosol eventually resulting in plasma membrane rupture (4). 
With the recent discovery of an intracellular signaling network, mediating necrosis, 
Hitomi et al. dispensed with the perception of necrosis as an unordered event. In 
order to emphasize the active nature of the observed cell death, and to distinguish it 
from accidental necrosis, the term necroptosis was introduced (63). As first molecular 
entity, RIP1 kinase has been recognized as a prerequisite for necroptotic cell death 
(64; 65). This finding gave also rise to the development of necrostatins, a class of 
small molecule inhibitors of RIP1 kinase function, which potently block necroptosis, 
but leave RIP1 effects on NF-κB and JNK signaling unaffected. Consequently, RIP1 
kinase function is considered dispensable for these signaling pathways, while it is 
essential for necroptosis (66). 
Necroptosis was found in response to stimulation by TNF-α (TNF receptor 1, 
TNFR1), tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), or Fas 
(also known as CD95) (67; 68). As these receptors also induce apoptosis by the 
extrinsic pathway, it becomes apparent, that death receptor stimulation can trigger 
more, than just one signaling pathway.  
In line with that notion, TNF-α signaling trifurcates at the site of TNFR1 stimulation 
leading either to NF-κB activation, apoptosis or necroptosis, depending on 
intracellular signaling (Figure 4).  
Upon TNF-α binding, the cytosolic part of the receptor recruits TNFR-associated 
death domain (TRADD), RIP1, cIAP1 and cIAP2 and TNFR associated factor 2 and 5 
(TRAF2 and 5). This aggregated structure is also referred to as complex 1. The 
signaling mode of complex 1 is controlled predominantly by regulative ubiquitination. 
In that respect, cIAP1 and cIAP2 ubiquitinate RIP1, which enables the formation and 
activation of the TAK1 kinase complex, thus triggering a NF-κB response (Figure 4). 
Under certain conditions, the membrane bound complex 1 changes to a proapoptotic 
cytosolic complex II (also termed DISC), that encompasses TRADD, Fas associated 
death protein (FADD) and caspase-8. Consequently, TNF signaling can be switched 
from prosurvival NF-κB to cell death signaling, forming complex II/DISC.  
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A central requirement for transition to complex II/DISC is the deubiquitination of 
RIP1. This process is mediated by CYLD, thus highlighting the pivotal role of CYLD 
in complex II formation. Following RIP1 deubiquitination, receptor-interacting protein 
3 (RIP3) is recruited to finalize complex II. Complex II has been shown to induce 
either apoptotic cell death, depending on caspase-8 (as outlined before), or 
necroptotic cell death, depending on RIP1 and RIP3. Downstream mechanisms of 
necroptosis have been closely associated with ROS production by various sources 
including mitochondrial glutamate dehydrogenase 1 (GLUD1), NADPH oxidase, 
NOX1 or lipoxygenases (69).  
 
Figure 4: Possible modes of TNF-α  receptor mediated signaling: NF-κB activation, apoptosis or 
necroptosis. (modified from Vandenabeele et al., 2010).  Upon tumor necrosis factor (TNF-α) 
binding, TNF receptor 1 (TNFR1) undergoes a conformational change, allowing for the assembly of 
complex I, which consists of TNF receptor associated death domain (TRADD), receptor-interacting 
protein 1 (RIP1), cellular inhibitor of apoptosis proteins (cIAPs), TNF receptor-associated factor 2 
(TRAF2) and TRAF5. On cIAP-mediated Lys63-ubiquitynation, RIP1 functions as a scaffold for the 
recruitment of transforming growth factor-β activated kinase 1 (TAK1), TAK1-binding protein 2 and 3 
(TAK2 and 3). This triggers then the canonical activation pathway of NF-κB. In contrast, if RIP1 is 
deubiquitinated by CYLD, RIP1 promotes cell death by two distinct pathways. When TNFR1 is 
internalized and undergoes the transition to complex II, its binding partners change to TRADD, FAS-
associated protein with a death domain (FADD), caspase-8, RIP1 and RIP3. TRADD and FAS are not 
consistently found in necrotic complex 2, their role therefore remains elusive. In apoptosis mode, 
caspase-8 triggers the activation of the classical caspase cascade, while RIP1 and RIP3 are cleaved 
and thus inactivated. When caspase-8 is inhibited (by a pharmacological inhibitor or genetic 
intervention) RIP1 and RIP3 initiate the effector mechanisms of necroptosis 
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1.8. Model system of HT-22 cells – ROS induced neuronal cell death 
 
Intracellular accumulation or uncontrolled release of reactive oxygen species (ROS) 
is a well accepted trigger of cell death in various neurodegenerative diseases and 
conditions of acute brain damage (70-72).  
The mechanisms underlying ROS mediated cell death include oxidation of 
membrane proteins, DNA-damage and mitochondrial membrane disruption. Due to 
the high relevance of ROS in neuronal cell death, this study employed the model 
system of HT-22 cells that well reflects ROS mediated cell death.  
HT-22 cells are derived from immortalized hippocampal neurons, rendering them an 
easily accessible and relevant system for the investigation of neuronal cell death. In 
HT-22 cells, cell death is induced by glutamate-exposure (oxytosis), but occurs 
independently of NMDA receptor stimulation, as these cells do not express glutamate 
receptors. Instead, glutamate-induced death is mediated through competitive 
inhibition of the xCT transporter, which leads to impaired import of cysteine, 
decreased glutathione levels and the subsequent accumulation of reactive oxygen 
species (ROS) (73; 74).  
The xCT-antiporter is a plasma membrane transport-protein, which mediates the 
import of cystine from the extracellular space and the concomitant export of 
glutamate. Elevated extracellular glutamate concentration thus causes a competitive 
blockade of the xCT-transport, leading to cystine and subsequently cysteine 
depletion in the cell (73-75). The resulting shortage of intracellular cystine/cysteine 
soon causes a decrease in glutathione-plasma levels. Given the crucial role of 
glutathione as a redox scavenger, reduced glutathione plasma levels give rise to 
excessive ROS formation and subsequent cell death. This form of cell death has 
been termed oxytosis (75). 
The induction of oxytosis by glutamate in this model system is therefore clearly 
different from glutamate dependent cell death in primary neurons, which is 
characterized by excitotoxic increases in intracellular Ca2+.  
As established previously, early initiation of cell death in HT-22 cells is closely linked 
to a rise in ROS due to an enhanced formation of lipidperoxides by activation of 
12/15 lipoxygenases (76). In a recent study in GPx4 knockout mice and murine 
embryonic fibroblasts, the glutathione peroxidase 4 (Gpx4) has been uncovered as a 
negative regulator of lipoxygenases, thereby linking decreasing glutathione levels 
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and reduced Gpx4 activity with enhanced 12/15 LOX activity and AIF dependent cell 
death (77).  
In response to the formation of ROS in HT-22 cells, the BH-3 protein Bid is activated 
and translocates to the mitochondria causing fragmentation and loss of mitochondrial 
membrane potential (78; 79). As a late event, AIF is released from the mitochondrial 
intermembrane space, translocates to the nucleus and induces DNA fragmentation 
and cell death (Figure 5) (78).  
In conclusion, excitotoxicity in primary neurons and oxytosis in HT-22 cells follow 
different initiating routes. The downstream pathways of neuronal apoptosis, however, 
are very similar in both models, thus highlighting the general suitability of HT-22 cells 
for studying neuronal cell death.  
 
 
Figure 5: Simplified Model of glutamate toxicity in HT-22 cells (modified from Tobaben, 2011). 
Exposure to elevated extracellular glutamate concentrations causes a competitive blockade of the xC-
Transporter that mediates the import of cystine and the export of glutamate. The resulting decrease in 
intracellular cystine levels halts glutathione synthesis and causes a fall in Gpx4 activity. In response to 
these events ROS formation is increased and LOX12/15 is activated, thereby further enhancing the 
load of intracellular ROS. Downstream activation and mitochondrial translocation of the BH-3 protein 
Bid causes mitochondrial disintegration and the release of proapoptotic factors, including AIF. AIF in 
turn translocates to the nucleus leading to DNA cleavage, thereby terminating cell death.
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2. Aims of this study 
 
The NF-κB pathway has been recognized as an important transcription factor 
counteracting pro-apoptotic influences and thereby inducing neuronal survival. 
Inhibition of the transcription factor p53 by pifithrin-α is an efficient approach to 
promote neuroprotection, which has been reported to rely at least partially on a 
mechanism of reciprocal transcriptional repression between NF-κB and p53. 
 
1. It was an aim of this study to investigate the general role of NF-κB in glutamate 
dependent neuronal cell death and to elicit the subunit-specific profile of the NF-
κB response. Further, it should be determined, which transcriptional targets of 
NF-κB were regulated in glutamate dependent neuronal cell death. 
 
2.  It was a second aim to elucidate the subunit-specific response of NF-κB in HT-22 
neurons treated with pifithrin-α and to determine how this affects the 
neuroprotective potential of pifithrin-α.  
 
3. The tumor suppressor CYLD has been implicated in NF-κB signaling, tumor 
formation and regulated necrotic cell death in various cell types and tissues. The 
impact of CYLD in neurons, however, has not been addressed so far. 
Therefore, a major aim of this study was to determine the role of CYLD in 
glutamate dependent neuronal cell death and to evaluate CYLD as a putative 
target of therapeutic strategies for neuroprotection. Further, it should be 
determined, which signaling pathways and molecular targets were affected by 
neuronal CYLD and how this translates into an effect on neuronal survival.  
 
4. The physiological relevance of the findings obtained in model systems of 
glutamate dependent neuronal cell death should be verified in a model of 
traumatic brain injury in mice. 
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3. Materials and Methods 
 
3.1. Cell culture 
 
All standard chemicals were obtained from Sigma-Aldrich (Taufkirchen, Germany) 
and Carl Roth (Karlsruhe, Germany) if not described otherwise. All buffers and 
solutions were prepared using demineralized, ultrapure water supplied by the SG 
Ultra Clear UV plus Reinstwassersystem (VWR, Darmstadt, Germany). Aseptic 
solutions were prepared using demineralized water, which was sterilized by a steam 
autoclave (Systec V-40, Systec GmbH, Wettenberg, Germany). Heat sensitive media 
and solutions intended for use in the cell culture were sterile-filtered using 0.22 µm 
filter sets (Sarstedt, Nürnbrecht, Germany). 
3.1.1. Cell culture material 
 
Cell Culture dishes including 96-, 24- and 6 well plates were acquired from Greiner 
Bio One (Frickenhausen, Germany). All Falcon-tubes including 50 ml, 15 ml, 2 ml, 
1.5 ml and 1 ml tubes were acquired from Sarstedt (Nürnbrecht, Germany). The 
xCELLigence system and the designated E-plates were obtained from Roche 
(Penzberg, Germany) 
3.1.2. Cell culture medium 
 
HT-22 cells were cultured in Dulbecco’s modified eagle medium (DMEM) containing 
4.5 mg/l glucose and 110 mg/l sodium pyruvate, which was supplemented further 
according to table 1. The medium stock and all additional supplements were obtained 
from PAA (Cölbe, Germany).  
 
Table 1: Dulbeco´s modified eagle medium 
DMEM-medium with 4.5mg/l glucose and 110 mg/l sodium pyruvate  440 ml 
Heat inactivated fetal calf serum (FCS) 50 ml 
L-alanyl-L-glutamine 200 mM 5 ml 
Penicillin 10,000 U/ml / Streptomycin 10 mg/ml 5 ml 
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3.1.3. Culturing HT-22 cells 
 
HT-22 cells were originally generated by Gerald Thiel and David Schubert (Salk 
Institute, San Diego, USA) and obtained from Gerald Thiel. HT-22 cells have been 
generated from HT-4 cells, a cell line originating from primary mouse hippocampal 
neurons. Immortalization has been achieved using a temperature-sensitive SV-40 T 
antigen (80).  
HT-22 stock cultures were kept in 75 cm2 culture flasks and split twice per week in a 
ratio 1:10 - 1:20. To this end, growth medium was removed and cells were washed 
once with warm phosphate buffered saline (PBS, table 3). After removing the 
washing buffer, 2-3 ml of Trypsin/EDTA solution (Table 4) were added and allowed to 
incubate for 2-5 minutes. Once the cellular layer has been defeated and cells were 
largely suspended, trypsination was stopped by adding 10ml of whole DMEM growth 
medium. Cells were centrifuged at 1000 rpm for 5 minutes, resuspended in 10 ml 
growth medium and counted using a counting chamber (Neubauer Zählkammer, 
Brand, Wertheim, Germany). Next, cells were seeded in the appropriate culture dish 
format, depending on the respective experimental plan. The specific cell densities 
used in the different formats are given in table 2. 
 
Table 2: HT-22 cells – cell densities 
Cell culture format Cell density cells/cm2 (cells/well) 
96 well plate ~ 22,500/ cm2 (7,000-8,000 cells/well)  
24 well plate ~ 180,000/cm2 (60,000 cells/well) 
6 well plate ~ 600,000/cm2 (200,000 cells/well) 
ibidi µ-slide 8-well plates ~ 36,000/cm2 (10,000-15,000 cells/well) 
E-Plate ~ 22,500/ cm2  - 30,000/ cm2   
 
Table: 3 Phosphate buffered saline (PBS), pH 7.4  
NaCl 9 g 
Na2HPO4 0.527 g 
KH2PO4 0.144 g 
HCl (0.1M) q.s. for pH adjustment 
Aqua demin. add to a final volume of 1000 ml 
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Table 4: Standard Trypsin/EDTA solution 
Trypsin (7.500 U/mg) 100 mg 
Ethylenediamine-tetra-acetic acid (EDTA)  40 mg 
PBS 200 ml 
 
3.1.4. Induction of cell death in HT-22 cells 
 
Cell death in HT-22 cells was induced 24 h after seeding by glutamate addition, 
typically at a final concentration of 3-5 mM. To this end, growth medium was replaced 
by culture medium supplemented with glutamate and with additional substances as 
indicated. Cell death was determined 8-12 h later, with samples taken at the 
appropriate time points for further analysis by absorption photometry, flow cytometry, 
epifluorescence microscopy and protein analysis. 
3.2. Primary embryonic cortical cultures 
 
3.2.1. Coating of culture dishes 
 
Primary embryonic cortical neurons were cultured in cell culture dishes, coated with 5 
% polyethylenimine (PEI, table 6). Coating was performed by incubating culture 
dishes with 5 % PEI for 2 h at room temperature (the exact composition of PEI-
solution is given in table 6). The dishes were then washed three times with aqua 
demin. and dried while exposed to UV-light for 30 minutes. Cell dishes then were 
covered with minimum essential medium (MEM+) and incubated overnight (Table 5). 
 
Table 5: Minimum essential medium (MEM+) 
MEM (powder) 9.39 g 
HEPES 0.238 g 
Glucose 10 g 
NaHCO3 2.2 g 
KCl 112 g 
Na-Pyruvate 0.12 g 
L-Glutamine 0.176 g 
Gentamycin-sulfate (10mg/ml) 1 ml 
NaOH (0.1 M) q.s. for pH adjustment to 7.2 
Aqua demin. add to a final volume of 1000 ml 
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Table 6: Polyethhylenimin (PEI) coating solution 
Boric acid 3.1 mg 
Borax 4.75 mg 
PEI 1 ml 
Aqua demin.  add to a final volume of 1000 ml 
 
3.2.2. Preparation of primary cortical cultures 
 
Primary cortical cultures were prepared as described previously (19). In brief, 
cortices were removed from embryonic C57black/6 mouse and rat brains (E17-18), 
trypsinized for 15 min (1 mg/ml) and incubated with DNAse 0.1 mg/ml for one minute 
(Sigma-Aldrich, Taufkirchen, Germany). Cortices were washed with HBSS, incubated 
with Trypsin-inhibitor (1 mg/ml, Sigma-Aldrich, Taufkirchen, Germany) and washed 
again. Afterwards, the cell suspension was triturated and allowed to stand for 2 
minutes. Precipitating cellular debris was removed and the cell suspension was 
subjected to centrifugation.  
Cells were resuspended in neurobasal medium (Stock from Invitrogen, Karlsruhe, 
Germany, final composition given in table 8) and counted using the counting 
chamber by Neubauer (Brand, Wertheim, Germany). The dissociated neurons were 
seeded onto polyethyleneimine-coated 6well culture dishes at a density of 400,000-
600,000 cells/well. The cultures were grown in neurobasal medium (PAA, Cölbe, 
Germany) supplemented as described in table 7. On day 5 in culture half of the 
medium was replaced by fresh media.  
 
Table 7: Hank´s balanced salt solution (HBSS) 
10x HBSS stock solution 100 ml 
HEPES 2.4 g 
Gentamycin-solution (10mg/ml) 1 ml 
NaOH (0.1 M) q.s. for pH adjustment to 7.2 
Aqua demin.  add to a final volume of 1000 ml 
 
Primary cortical neurons were cultured in neurobasal medium (Table 8), 
supplemented with 2% B27 (Invitrogen, Karlsruhe, Germany).  
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Table 8: Neurobasal medium 
Neurobasal medium 490 ml 
4-(2-Hydroxyethyl)piperazine- 1-ethanesulfonic acid 
(HEPES) 
575.3 mg 
L-Glutamin 88.8 mg 
Gentamycin-sulfate (10 mg/ml) 0.5 ml 
B-27 supplement 10 ml 
NaOH (0.1 M) q.s. for pH adjustment to 7.2 
 
3.2.3. Induction of excitotoxic cell death in primary cortical neurons 
 
On day six in culture, primary cortical neurons were exposed to glutamate for 1 h at a 
final concentration of 200-500 µM. To this end growth medium was removed, cells 
were washed once with warm EBSS and then exposed to glutamate diluted in EBSS 
(Table 9). If indicated, additional substances such as necrostatins were co-
administered. Afterwards, the original growth medium, which had been collected 
before the treatment, was re-applied to the cells, and supplemented with the 
respective compounds, as indicated. Cell death was analyzed similarly as for the 
other damage regime.  
 
Table 9 Earl´s balanced salt solution (EBSS) 
10x EBSS stock solution 100 ml 
NaHCO3 2.2 g 
NaOH (0.1 M) q.s. for pH adjustment to 7.2 
Aqua demin. add to a final volume of 1000 ml 
 
3.3. Chemicals and reagents 
 
All standard chemicals were obtained from Sigma-Aldrich (Taufkirchen, Germany) 
and Carl Roth (Karlsruhe, Germany) if not described otherwise. All buffers and 
solutions were prepared using demineralized, ultrapure water supplied by the SG 
Ultra Clear UV plus Reinstwassersystem (VWR, Darmstadt, Germany). 
Demineralized water for aseptic preparation of solutions was sterilized beforehand 
using a steam autoclave (Systec V-40, Systec GmbH, Wettenberg, Germany). Heat 
sensitive media and solutions intended for use in the cell culture were sterile-filtered 
using 0.22 µm filter sets (Sarstedt, Nürnbrecht, Germany). 
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The following compounds were used for induction or prevention of cell death: 
 
Reagents: soluble, recombinant murine TNF-α, Necrostatin 1, Necrostatin 5, 
Necrostatin-7 (#ALX-522-009, #AP-309-UU20, #ALX-430-169, #ALX-430-170, all 
Enzo Life Science, Plymouth Meeting, USA), Geldanamycin (#EI-280-0001, Enzo 
Life Science, Plymouth Meeting, USA), ABT-737 (#S1002, Selleck Chemicals, 
Houston, USA), PFT-α (P4359; Sigma-Aldrich, Munich, Germany), L-Glutamic acid 
(G6642; Sigma-Aldrich, Munich, Germany), SM-164, kind gift from Shamoeng Wang, 
University of Michigan. 
3.3.1. Primary antibodies 
 
All primary antibodies were used at a dilution of 1:1000 for WB and 1:200 for 
immunocytochemistry (ICC). Antibodies intended for use in western blot applications 
were diluted in Tris-buffered saline containing 0.05 % Tween 20 and 5 % skim milk 
powder, if not stated otherwise (Table 10), (Sigma-Aldrich, Munich, Germany). In this 
study, the following antibodies have been used: anti-CYLD antibody diluted 1:100 
(#sc74434 Santa Cruz Biotechnology, Santa Cruz Biotechnology, CA, USA), anti-
RIP1 antibody (#610459, BD Biosciences Pharmingen, Heidelberg, Germany) anti-
RIP3 (#2283, ProSci, San Diego, USA), anti COX IV (#4844, Cell Signaling 
Technology, Beverly, USA) anti pan-cIAP (#3400, R&D systems, Minneapolis, USA), 
anti-IkBα, PIkBα and RelB (#4814, #9246, #4953, Cell Signaling Technology, 
Beverly, USA), anti neuronal nuclei (#MAB377, Millipore, Billerica, USA), anti p50, 
p52, p65 (#ab7971, #ab7972, #ab7970, Abcam, Cambridge, UK), anti cRel, anti Bcl-
3 (#sc-71, #sc-185, Santa Cruz Biotechnology, CA, USA) anti TNFα (#AB-410-NA, 
R&D systems, Minneapolis, USA), anti-α-tubulin monoclonal antibody (#T6074 
Sigma-Aldrich, Munich, Germany), anti-Aktin (#691001, MP-Biomedicals, Solon, 
USA).  
3.3.2. Secondary antibodies 
 
For Western blot analysis horseradish peroxidase (HRP) labeled secondary 
antibodies were used (All Vector Labs, Burlingame, California, USA). Secondary 
antibodies were diluted 1:4000 in Western-blotting buffer consisting of Tris-buffered 
saline with 0.05 % Tween 20 and 5 % skim milk powder (Sigma-Aldrich, Munich, 
Germany). For immunocytochemistry, fluorochrome coupled antibodies Alexa488 
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and DyLight 633 anti-mouse and rabbit antibodies were used (Invitrogen, Karlsruhe, 
Germany and Thermo Fisher Scientific, Rockford, USA). For ICC, secondary 
antibodies were diluted 1:200 in phosphate buffered saline (1x PBS) containing 3 % 
horse serum (Invitrogen, Karlsruhe, Germany.  
3.3.3. siRNA sequences 
 
Sequence specific siRNA duplexes for CYLD (5´UGAAAUGACUGAGCGAUAA3´) or 
5’ CUGCAUUGAUGAUACGAUA3’, RIP1 (5’GAAUGAGGCUUACAACAGA3), 
CyclinD1 (pool of 4, equally)’ (ACUAUUUCAUCCCUACCGCtg3’), 
(5’GCGGUAGGGAUGAAAUAGUtt3’) (5’CGAUUUCAUCGAACACUUCtt3’), 
(5’GAAGUGUUCGAUGAAAUCGtg3’) and a nonfunctional mutant (scrambled) 
siRNA duplex 5’ UAAUGUAUUGGAACGCAUATT3’ were purchased from MWG 
(Eurofins MWG Operon, Ebersberg, Germany). The validated smart-pool ON-
TARGETplus siRNA for RIP3 (5´UCAAGAUCGUGAACUCGAA´3; 
5´CAAGUUCGGCCAAGUAUGA3’; 5´GGUAAAGCAUUAUCUGUCU3’; 
5’ACACGGCACUCCUUGGUAU3’ and Bcl-3 5’GACCUUUGAUGCCCAUUUA3’; 5’ 
UCGCUGUGGUCCAGAAUAA3’; 5’ CGUGAACGCUCAGAUGUAU3’; 
5’AAGUAGACGUCCAUAACAA3’ were all purchased at Dharmacon (#L-049919-00-
0005, #M-045102-00-0005, Dharmacon, Lafayette, USA). 
3.3.4. Plasmids 
 
The overexpression vector for murine CYLD was purchased form Open Biosystems 
(clone-id 3983771, Huntsville, USA). The mitoGFP (mGFP) vector used as a control 
vector was a gift from Andreas Reichert (Goethe University Frankfurt, Germany). NF-
κB reporter plasmid was obtained from BD Bioscience (#6053-1, Clontech, 
Heidelberg Germany). 
All plasmids were amplified using the QIAGEN Plasmid Plus Midi kit (Qiagen, Hilden, 
Germany). After resuspension, plasmid concentration was determined by UV 
absorption using a NanoVue Plus Spectrophotometer (Implem, GE Healthcare 
Europe GmbH, Freiburg, Germany). 
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3.3.5. PCR-primer 
 
T7-Primers for DICER siRNA generation: CYLD fw 
5’GCGTAATACGACTCACTATAGGGAGACTCAGCCTATTTAGAAACAGACT3’, rv 
5’GCGTAATACGACTCACTATAGGGAGATACACCTCTTGACATAAAGGC3’,  
CYLD primer for mRNA analysis (T7 primers may be used as well) fw 
5’CTCAGCCTATTTAGAAACAGACT3’, rv 5’ATACACCTCTTGACATAAAGGC3’, 
murine GAPDH fw5`-CGTCTTCACCACCATGGAGAAGGC-3`, rv 5`-
AAGGCCATGCCAGTGAGCTTCCC-3. CYLD exon4 fw 
5’ACAACATGGATGCCAGGTTG3’, rv 5’CCGCTAATAAAGGTCCTCTG3’, CYLD 
LACZ fw 5’GCATCGAGCTGGGTAATAAGCGTTGGCAAT3’, rv 
5’GACACCAGACCAACTGGTAATGGTAGCGAC3’ 
All primers were synthesized at MWG (Eurofins MWG Operon, Ebersberg, 
Germany). Oligo (dt) 15 primers were obtained from Promega (Madison, USA). 
3.4. Kits  
 
The following list encompasses the kits used for this study: 
 
Annexin-V-FITC Detection Kit  Promokine, Heidelberg, Germany 
Bodipy (581/591 C11) Invitrogen, Karlsruhe, Germany 
JC-1 Invitrogen, Karlsruhe, Germany 
RNAiMax Invitrogen, Karlsruhe, Germany 
Pierce BCA Kit Perbio Science, Bonn, Germany 
NucleoSpin RNA II Kit  Machery & Nagel, Düren, Germany 
Nucleus extraction kit Active Motif, Carlsbad, USA 
Luciferase assay sytem  Promega, Madison, USA 
QIAGEN Plasmid Plus Midi  Qiagen, Hilden, Germany 
SuperScript III (One Step RT-PCR) Invitrogen, Karlsruhe, Germany 
M-MLV Reverse Transcriptase Promega, Madison, USA 
Dicer siRNA generation kit Genlantis, San Diego, USA 
DNA tissue extraction kit Peqlab, Erlangen, Germany 
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3.5. Transfection methods 
 
3.5.1. siRNA transfections 
 
siRNA was transfected using RNAiMax transfection reagent (Invitrogen, Karlsruhe, 
Germany) according to the manufacturer´s instructions. The transfection was carried 
out in a 24 well format using a „reverse-transfection“ protocol. Accordingly, siRNA 
duplexes were prediluted in OptiMEM medium at a concentration of 120-300 nM. 
Eleven µl of RNAiMax transfection reagent was added to 1 ml of the premixed 
siRNA. After repeated inversion of the tubes, 100 µl of the liposomal complexes were 
transferred into each well of the 24-well plate. Following 20 minutes of incubation, 
500-550 µl of cell suspension (60,000 HT-22 cells/ml in DMEM without antibiotics) 
were added to each well. After gentle shaking of the culture plates, HT-22 cells were 
returned to the incubator. Samples were taken after 24 h for RNA analysis and after 
48-72 h for protein extracts respectively. If a transfer to another cell culture format 
was necessary, HT-22 cells were reseeded 48 h after transfection.  
3.5.2. Plasmid transfection  
 
HT-22 cells were seeded in antibiotic-free medium at a density of 60,000 cells/well in 
a 24-well format. Twenty-four h later and shortly before transfection, medium was 
changed to 900 µl/well of antibiotic free and serum free DMEM medium. 
Polyethylenimin (PEI, was a kind gift from BASF, Germany) particles and DNA-
plasmids were diluted in glucose solution (5%) at a concentration of 28.8 µg/ml and 
30 µg/ml respectively. Equal amounts were mixed and incubated for 20 minutes to 
allow the formation of PEI polyplexes. One hundred µl of these polyplexes were 
added to each well giving rise to a final concentration of 1-1.5µg of PEI/ml and 1-2 µg 
of plasmid/ml. Following another incubation period of 4 h, medium was replaced by 
whole DMEM medium. 
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3.6. Cell viability assays 
 
For detection of cell death by MTT-assay, HT-22 cells were seeded in 96-well plates, 
or alternatively in 24-well plates. Primary cortical neurons were cultured in 6-well 
plates and cell death was evaluated by manual counting of pyknotic nuclei. For 
detection of cell death by Annexin-V and propidium iodide staining, HT-22 cells were 
seeded in 24-well plates.  
3.6.1. MTT assay 
 
The MTT assay relies on the reductive processing of 3-(4,5- dimethylthiazol- 2-yl)-
2,5-diphenyltetrazolium bromide (MTT) to formazan by either a lyosomal/endosomal 
compartment or mitochondria (81). As the MTT turnover primarily reflects metabolic 
activity, a direct correlation with cell death needs to be established separately using 
further cell death assays. The reduction of MTT is accompanied by a pronounced 
change in absorption characteristics, which is easily detected by absorptive 
spectroscopy.  
MTT-reagent (Sigma-Aldrich, Taufkirchen, Germany) is dissolved in PBS at an 
appropriate concentration of e.g. 1.5 mg/ml. MTT reagent is then added to the culture 
medium of HT-22 cells at a final concentration of 0.25 – 0.5 mg/ml. Following an 
incubation of 1h at 37° C, medium was removed and the culture plates were 
transferred to a -80° C freezer. After at least 1 h at -80° C formazan crystals were 
dissolved in 100 µl DMSO/per well (Sigma-Aldrich, Taufkirchen, Germany) under 
continuous shaking at 37° C. Absorption was measured 1h later at 570 nm using a 
microplate reader (Fluostar OPTIMA, BMG Labtech, Offenburg, Germany). 
Background was detected at 630nm and substracted accordingly. Cell viability was 
expressed as absorption level relative to controls. For statistical analysis the 
experiment was repeated three times.  
3.6.2. DAPI staining 
 
Primary cortical neurons from embryonic mice or rat (day 17-18) were cultured in 6 
well culture dishes as described before. Following glutamate exposure over the 
respective time, cells were washed once with PBS and fixed with 4% 
paraformaldehyde for 20 minutes. Following another washing step with PBS, cells 
were exposed to 4′,6-diamidin-2-phenylindol (DAPI) at a final concentration of 1 
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µg/ml in PBS for 5-10 minutes. Replacement of DAPI solution with PBS was 
performed optionally to reduce background fluorescence, when required. DAPI-
stained nuclei were visualized using an epifluorescence-microscope with a 40x 
magnification and 340 nm for excitation (DMI6000B, Leica, Wetzlar, Germany). 
Pyknotic cells showing highly condensed or fragmented nuclei were considered 
apoptotic. Counting and anaylsis of pyknotic nuclei was performed blind to the 
treatment group. An average of four hundred cells, grown in five different regions, 
were counted per well. Each experiment was repeated three times.  
3.6.3. Annexin-V/propidium iodide staining  
 
The externalisation of phosphatidylserine is a well-recognized event occurring in cells 
undergoing apoptotic cell death. Binding of fluorescein isothiocyanat (FITC) labeled 
Annexin-V is commonly used to detect phosphatidylserine residues present on the 
outer cellular membrane of apoptotic cells. Necrotic cell death in turn can be 
visualized by propidium iodide, a dye, which upon binding to DNA shows a 
pronounced shift in absorption characteristics. Under physiological conditions cellular 
membranes are impermeable for propidium iodide, resulting in no fluorescent 
staining of nuclei. Membrane leakage, occurring in necrotic cells, however, 
significantly increases the cellular permeability for propidium iodide, thus staining 
nuclei of cells prone to undergo necrosis.  
For evaluation of cell death using Annexin-V and propidium iodide, HT-22 cells were 
harvested using 1 x TE, washed once with PBS and incubated in 500 µl binding 
buffer supplied as a component of the Annexin-V-FITC Detection Kit (PromoKine, 
Heidelberg, Germany). Five µl of the AnnexinV- and propidium iodide stock solution 
were added. Apoptotic and necrotic cells were detected using a FACScan (Becton, 
Dickinson and Company), Annexin-V and propidium iodode fluorescence was exited 
at a wavelength of 488 nm and emission was detected at 530±40 nm and at 680±30 
nm respectively. To avoid detection of cellular debris and clusters, cells were gated 
accordingly using forward and sideward scatter. For each sample 10,000 cells were 
analyzed. The experiment was repeated three times.   
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3.6.4. Detection of the mitochondrial membrane potential - JC-1 assay 
 
Reduction of 5, 5', 6, 6'- tetrachloro-1, 1', 3, 3'-tetraethylbenzimidazolylcarbocyanine 
iodide (JC-1) was applied to evaluate mitochondrial membrane potential in HT-22 
cells. HT-22 cells were stained with JC-1 according to the manufacturer’s protocol  
(Invitrogen, Karlsruhe, Germany) and analyzed by fluorescence-activated cell sorting 
(FACS). Approximately 10 hours after glutamate treatment, JC-1 was added to each 
well at a final concentration of 2 µM and incubated for 30 min. As a positive control, 
carbonyl cyanide m-chlorophenylhydrazone (CCCP) was used, which causes a near 
complete depletion of the mitochondrial membrane potential following an incubation-
period of 15 minutes. Cells were harvested with standard Trypsin/EDTA (Sigma-
Aldrich, Taufkrichen, Germany) in 1x PBS. To enhance trypsination, cells were 
carefully pipetted up and down several times and collected in full DMEM medium. 
Following centrifugation at 1,000 x g for 5 minutes at room temperature, cells were 
washed once with 1x PBS, and kept in 0.5 ml 1x PBS on ice. Analysis of JC-1 
fluorescence was conducted using a FACScan (BD Bioscience, Heidelberg 
Germany). JC-1 green fluorescence indicates mitochondrial uptake of the dye, while 
JC-1 red fluorescence indicates intact mitochondrial membrane. JC-1 green 
fluorescence was excited at 488 nm and emission was detected using a 530 ± 40 nm 
band pass filter, JC-1 red fluorescence was excited at 488 nm and emission was 
detected using a 613 ± 20 nm band pass filter. Cells were gated to exclude cellular 
debris and cell clusters. At least 10,000 cells were analyzed per sample. 
3.6.5. Detection of lipid peroxidation – BODIPY assay 
 
For detection of cellular lipid peroxidation, cells were loaded with 2 µM BODIPY 
581/591 C11 (Invitrogen, Karlsruhe, Germany) for 60 min in standard medium. 
Incubation was carried out at the indicated time points, usually 10 h post-glutamate 
exposure. Cells were washed once with PBS prior to harvesting them with standard 
Trypsin/EDTA (1x TE, Sigma-Aldrich, Taufkrichen, Germany) in 1x PBS. To enhance 
trypsination, cells were carefully pipetted up and down several times and collected in 
full DMEM medium. Following centrifugation at 1000 x g for 5 min. at room 
temperature, cells were washed once with 1x PBS, and kept in 0.5 ml 1x PBS on ice. 
Flow cytometry was performed using 488 nm UV line argon laser for excitation and 
BODIPY emission was recorded on channels FL1 at 530 nm (green) and FL2 at 585 
nm (red). Data was collected for each sample from 10,000 cells. Increased lipid 
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peroxidation induces a shift from red to green fluorescence that can be detected by 
flow cytometry (FACScan, BD Bioscience, Heidelberg Germany). 
 
3.7. Detection of cell death by impedance measurement – The 
xCELLigence system 
 
3.7.1. Measurement of cellular impedance for analysis of cell death 
 
Neuronal cell death follows distinct pathways, including apoptosis, autophagic cell 
death and necrosis (5). Though progression and execution of these pathways differ 
significantly, cell death is usually accompanied by clear changes in cellular 
morphology, allowing also for visual differentiation of living and dead cells. By 
measuring cellular impedance using e.g. the commercially available xCELLigence 
system (Roche Diagnostics, Penzberg, Germany), these morphological changes can 
be tracked indirectly and applied for evaluation of cell death.  
The xCELLigence system is a microelectrode biosensor designed for the use with 
dedicated multi-well plates (E-plates®, Roche Diagnostics, Penzberg, Germany), 
which feature an integrated network of microelectrodes in each well (Figure 6A). For 
measuring impedance between these electrodes a low AC excitation voltage level 
(mV range) and a resulting minor electrical current (µA range) are applied, which 
have been proven to be without any effect on cellular function. The impedance 
readout by the xCELLigence system is presented as arbitrary Cell Index values, 
expressing changes between baseline and each measurement point, according to 
the following equation CI = (Zi – Z0)/15. In this equation, Zi is the impedance at any 
given time point and Z0 the background signal.  
Usually, impedance measurements in aqueous solution are influenced by the 
temperature, the shape of the electrodes, the ionic strength and additional insulating 
material as for instance cell-layers covering the electrodes. Consequently, if the three 
factors first mentioned are kept even, the impedance readout only depends on the 
degree of insulation inflicted by cells grown on top of the electrodes. To highlight this 
dependence, the term cellular impedance is commonly used for describing 
impedance analyses in cell culture systems. As indicated in figure 6B, changes in 
cellular impedance occur either, because of increases in cell number (proliferating 
cells), an increase in the outer cell surface (differentiation) or altered attachment 
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properties (e.g. cellular detachment during cell death). In conclusion, all these 
changes in impedance, result from an altered insulating-capacity of the cellular layer. 
In a previous study, we successfully validated the correlation between cellular 
impedance readouts and cell death for HT-22 cells, rendering the xCELLigence 
system a fast and easy approach for confirming viability data gained by ordinary 
assays (82).  
The xCELLigence system, however, adds more to a deeper understanding of cell 
death processes, as it allows to unravel cell death kinetics and to distinguish between 
transient or permanent protective effects. This is due to the nature of real time 
detection, an inherent feature of the xCELLigence system. Nonetheless, certain cell 
types will prove inadequate for impedance measurements, for which reason 
suitability needs to be confirmed individually when starting with a new cell type (28).  
 
 
Figure 6: Schematic overview of the measurement principle of cellular impedance. (A) Each well 
of the culture dish features a bottom with embedded gold-electrodes. The electrode array has a 
minimal distance of 30 µm between the electrodes. The right picture shows a magnified upright view of 
the electrode array. (B) Cells were seeded on top of the electrode-covered surface of the culture dish. 
After attaching to the bottom of the well, the cells partially insulate the electrodes, causing a rise in 
impedance. With an increasing cell density, the cells have a greater overall insulating capacity, 
showing in a further increase in impedance. Inflicting cellular damage and cell death causes changes 
in membrane morphology, cellular shrinkage and detachment, resulting in a decrease in cellular 
impedance. 
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3.7.2. The xCELLigence system in HT-22 cells 
 
Using the xCELLigence system for detection of proliferation and cell death in HT-22 
cells, an average cell density of 22,500 cells/cm2 proved most appropriate. Prior to 
seeding the cells, background impedance was determined using 100 µl of cell culture 
medium. Next, cell suspension was added to a total of 200 µl/well. Due to the great 
sensitivity of the system, changes in temperature strongly influence the 
measurement, for which reason, treatment procedures outside of the incubator were 
conducted at the utmost speed.  
Treatment of HT-22 cells was started as early as 20-24 h after seeding, when the cell 
index exceeded a value of 1. For any treatment, a mere 100µl were removed and 
replaced by the corresponding amount containing the respective components of 
interest. Cell-index values were recorded using RTCA Software 1.2 (Roche 
Diagnostics, Penzberg, Germany). Each experiment was repeated 3 times.  
After concluding each experiment, E-plates were recycled using the following 
scheme. After removing media and washing the plates twice with demineralised 
water, standard Trypsin/EDTA (1x TE, Sigma-Aldrich, Taufkirchen, Germany) was 
added for 15-20 minutes. Afterwards 1xTE was removed, the plates were washed 
further 3 times and irradiated with UV light for 30 minutes to reassure sterility. Plates 
handled this way can be reused several times. However, before starting a new 
experiment structural integrity and functionality of the electrodes should be assessed 
by evaluating the homogeneity of the impedance profile of the E-plate under control 
conditions. This can be done easily by choosing the well analysis tab in the RTCA 
software. 
 
3.8. Immunocytochemistry 
 
3.8.1. Immunocytochemistry of NF-κB subunits, RIP1 and RIP3 
 
Immunocytochemical stainings of HT-22 cells were carried out in ibidi 8-well plates 
(Ibidi GmbH, Munich, Germany) at a density of 15,000 cells/well. Following the 
respective treatment regime, cells were washed once with PBS, fixed with 4 % PFA 
in PBS for 20 minutes and washed again with 1x PBS. Afterwards, the cells were 
permeabilized by 0.4 % Triton X-100 (Sigma- Aldrich, Taufkirchen, Germany) in 1x 
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PBS for 5 minutes. Blocking of unspecific binding sites was achieved by incubation 
with blocking solution containing 3 % horse serum (Invitrogen, Karlsruhe, Germany) 
in 1x PBS for 30 minutes. Cells were then treated with the primary antibodies listed in 
the respective section. Antibodies were diluted 1:100 in blocking solution and 
incubated overnight at 4 °C. After washing with PBS three times, one of the 
appropriate secondary antibodies enlisted above was incubated in blocking solution 
for further 90 minutes at room temperature.  
After counterstaining the nuclei with DAPI (1 µg/ml), cells were washed again twice. 
Background fluorescence caused by unspecific binding of secondary antibodies was 
determined by staining cells only with the secondary antibody. Images were taken 
using a confocal laser-scanning microscope (Axiovert 200, Carl Zeiss, Jena, 
Germany) equipped with an UV and an argon laser. Depending on the excitation 
requirements for the secondary antibody, light was delivered at 488 or 633 nm, DAPI 
was excited at 364 nm. For digital imaging the software LSM Image software (Carl 
Zeiss, Jena, Germany) was used. 
3.8.2. MitoTracker staining and evaluation of mitochondrial morphology 
 
Mitochondrial morphology in HT-22 cells (grown in ibidi slides, 15,000 cells/well) was 
visualized using MitoTracker dyes supplied by Invitrogen (Karlsruhe, Germany). 
MitoTracker DeepRed was dissolved in DMSO at a final stock-concentration of 50 
µM and kept protected from light. MitoTracker reagent was then diluted 1:250 in 
culture medium and added to the cells (final working concentration 200 nM) for 20 
minutes before starting the respective treatment. Cells were washed once with warm 
culture medium after incubation with MitoTracker, to assure complete removal of the 
dye. After completing the experiment, cells were washed with PBS, fixed with 4% 
PFA and washed again twice with PBS.  
For investigation of mitochondrial localization, subsequent immunocytochemical 
stainings for RIP1 and RIP3 were performed following the instructions given above. 
Images were taken using a confocal laser scanning microscope running LSM Image 
software (Axiovert 200, Carl Zeiss, Jena, Germany). MitoTracker DeepRed 
fluorescence was excited at a wavelength of 633 nm (band pass filter) and emissions 
were detected using a 670 nm long pass filter. Evaluation and classification of 
mitochondrial morphology was performed as described before (79). Following this 
classification scheme, mitochondria were counted manually and categorized in 3 
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subgroups, depending on the degree of fragmentation. Accordingly, category 1 
reflects the intact tubular network of mitochondria found under control conditions, 
whereas category 2 and 3 indicate an increasing number of fragmented 
mitochondria.  
As the studies by Grohm et al. revealed, increased mitochondrial fragmentation was 
accompanied by an apoptotic phenotype, showing e.g. in nuclear condensation and 
the peri-arrangement of the mitochondrial fragments. For the quantification of 
mitochondrial morphology, at least two hundred cells per well were counted and 
experiments were performed at least three times. Counting was performed blinded to 
the treatment history. 
3.9. Protein analysis  
 
3.9.1. Buffers for Western blot analysis 
 
Table 10: Buffers for Western blot analysis  
Stacking gel 3.5%  
  
0.5 M Tris HCl solution pH 6.8 2.5 ml 
Acrylamid/bisacrylamide (37.5 : 1) 30% 1.2 ml 
Sodium dodecyl sulfate solution 10% 0.1 ml 
Ammoniumpersulfate solution 10% 0.05 ml 
Tetramethylethylenediamine TEMED 0.01 ml 
Bidest dH20 add to a final volume of 10 ml 
  
Collection gel 12.5%  
  
1.5M Tris HCl solution pH 8.8 2.5 ml 
Acrylamid/bisacrylamide (37,5:1) 30 % 3.34 (4 ml for 12.5% gels) 
Sodium dodecyl sulfate solution 10 % 0.1 ml 
Ammoniumpersulfate solution 10 % 0.05 ml 
Tetramethylethylenediamine TEMED 0.01 ml 
Bidest dH20 add to a final volume of 10 ml 
  
1 x Electrophoresis-buffer  
  
Tris base 3 g 
Glycine 14.4 g 
Sodium dodecyl sulfate (SDS) 1 g 
Bidest H2O add to a final volume of 1000 ml 
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1x Transferbuffer, pH 8.3  
  
Tris base 3 g 
Glycine 14.4 g 
Methanol 100 ml 
HCl 0.1M q.s 
Bidest dH20 add to a final volume of 1000 ml 
  
1x TTBS, pH 7.5  
  
Tris Base 2.4 g 
NaCl 29.2 g 
HCl 0.1M q.s. 
Bidest dH2O add to a final volume of 10 ml 
  
1x Blocking buffer  
  
Skim milk powder 25 g 
TBST add to a final volume of 500 ml 
  
Stripping buffer, pH 2  
  
Glycine 15 g 
Sodium Dodecyl sulfate (SDS) 1 g 
Tween 20 10 ml 
HCl conc. q.s. 
Bidest dH2O add to a final volume of 1000 ml 
  
5x sample buffer Western blot  
  
1 M Tris-HCl pH 6.8 70 ml 
Glycerol 30 ml 
D,L-dithiotreitol (DTT) 9.3 g  
SDS 10 g 
β-Mercaptoethanol 1 ml 
Bromophenol blue sodium salt 12 mg 
 
3.9.2. Protein extraction and measurement of protein content  
 
For protein analysis HT-22 cells and primary neurons were seeded in 6-well plates at 
a density of 200,000 cells/well for HT-22 cells and 400,000 cells/well for primary 
neurons. To avoid the risk of protein degradation cells were kept on ice during the 
whole process of extraction. After removing the culture medi
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once with PBS. To avoid loss of detached cells, washing buffer was collected and 
centrifuged.  
The remaining pellet was washed again and pooled subsequently with the main 
extract. Cells were removed from the culture dishes using cell scrapers (Sarstedt, 
Nümbrecht, Germany) and lysed in protein extraction buffer adjusted to pH 7.8 (0.25 
M D-Mannitol 0.05 M Tris-base, 1 mM EDTA, 1 mM EGTA and 1% Triton X-100). 
The buffer was supplemented with 1 tablet complete mini protease inhibitor cocktail 
and if required 1 tablet phosphatase inhibitors PhosphoSTOP (both Roche, 
Mannheim, Germany). For long term storage protein samples were stored at -80° C. 
Prior to determining protein content, samples were centrifuged at 13,000 U/min at 4° 
C for 10 min. The supernatant was transferred to a fresh cup and analyzed 
subsequently for protein content using the Pierce BCA kit according to the 
manufacturer’s instructions (Perbio Science, Bonn, Germany).  
The colorimetric reaction of the BCA assay consists of two separate reactions. In a 
first step, Cu2+ is reduced to Cu1+ by certain aminoacids including tryptophane and 
tyrosine. In the second step, Cu1+ is chelated by bicinchoninic acid, giving rise to a 
deeply colored complex, whose concentration is determined by absorptive 
spectoscropy at 562 nm. Protein content is then determined using a standard curve. 
Each sample was measured after incubating 2.5 µl of protein lysate with 200 µl of 
reaction buffer at 60°C for 30 minutes. Samples were cooled on ice to halt the 
reaction and equal amounts of each sample were transferred to a multi-well plate for 
spectrophotometric analysis, which was carried out using a microplate reader 
(Fluostar OPTIMA, BMG Labtech, Offenburg, Germany). 
3.9.3. Immunoprecipitation 
 
Immunoprecipitation was performed using DynaBeads coupled with Protein A 
according to the manufacturer´s protocol (Invitrogen, Karlsruhe, Germany). Briefly, 
50 µl of DynaBeads suspension was pulled down and resuspended in 200 µl of PBS, 
containing 10 µg of the antibody meant for pulldown and 0.05 % of Tween, to prevent 
clogging of the beads. Following an incubation period of 30 min, the beads were 
washed with TBST (0.05 % Tween) and crosslinked by 2.5 mM Bis-
Sulfosuccinimidyl-substrate for another 30 minutes (BS3, Thermo Fisher Scientific, 
Rockford, USA). Crosslinking was terminated by adding 1 M TRIS-buffer (pH 7.5) to 
a final concentration of 50 mM. The beads were washed again and incubated with 
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the protein samples for 2-5 h, depending on the affinity at 4°C. Immunoprecipitation 
was carried out using 1.25 mg of protein.  
Importantly, the amount of lysate of the different samples, with which the beads are 
incubated, needs to be adjusted to the same volume using protein lysis buffer. After 
thorough washing, elution of immunoprecipitated proteins was performed at 90°C 
using 70 µl of 2.5x sodium dodecyl sulfate (SDS) -sample buffer. Samples were 
stored at -80°C for later analysis by Western blot. 
3.9.4. Generation of polyacylamide gels for Western Blot analysis 
 
Gels were prepared using BIO-RAD gel casting stand and casting frames. Gels were 
prepared using a polyacrylamide separation gel with a concentration of 10-12.5 % 
and a stacking gel with 3.5 %. The specific buffers used for generation of gels and 
subsequent electrophoresis are given in table 10. 
3.9.5. Gel electrophoresis 
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) has been 
used to separate proteins according to their different molecular-mass, thus providing 
samples for further analysis by Western blot. Prior to electrophoresis, samples were 
prepared using 20-30 µg of raw protein extract, adjusting the volume to 24 µl with 
aqua demin. and adding another 6 µl of 5x SDS sample buffer. Samples were heated 
at 95°C for 5 minutes and loaded onto the gel after reaching room temperature. For 
comparative evaluation of molecular-mass, 5-10 µl of PageRulerTM Plus Prestained 
Ladder (Fermentas, St. Leon-Rot, Germany) were loaded next to the samples. 
Electrophoresis was performed initially at 60 V for approximately 30 min to allow for 
sample collection and increased later to 120 V. Following electrophoretic separation, 
proteins were blotted on a polyvinylidenfluorid membrane (PVDF, Bio-Rad, Munich, 
Germany) according to the recommendations by Bio-Rad at 15 V for 60 minutes. 
 
PVDF-membranes were first activated in methanol for 2 minutes and then incubated 
for 10 minutes in 1 x transfer buffer before blotting. Meanwhile Whatman-blotting 
paper and the acrylamide gel were incubated for 10 minutes in transfer buffer. 
Blotting was carried out, by stacking one layer of Whatman-paper on top of the 
anodic plate, followed by the second layer the PVDF-membrane, the acrylamide gel 
as the third, and another final layer of Whatman-paper on top. Blotting was carried 
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out in a Trans-Blot SD semi-dry transfer cell (Bio-Rad, Munich, Germany) using extra 
thick Whatman filter paper (Bio-Rad, Munich, Germany) and 1x transfer buffer 
containing 10 % of methanol.  
After blotting for 1h, the PVDF-membranes were transferred directly to 5% Western-
blot blocking buffer and incubated for 1 h at room temperature. Then the blots were 
probed with the primary antibodies (diluted in blocking buffer) overnight at 4°C. The 
next day, membranes were washed twice with TBST for 5 minutes and probed with 
the appropriate HRP-conjugated secondary antibody in 5 % blocking solution for one 
hour. Following 3 washing steps with TBST for 15 minutes each, membranes were 
incubated with chemiluminescent substrate solution HRP-Juice (PJK GmbH, 
Kleinblittersdorf, Germany). Chemiluminescent signals were recorded and quantified 
by densitometric analysis using the semi-automated Chemidoc-XRS Imaging System 
and the dedicated Quantity One software package (both, Bio-Rad, Munich, 
Germany). 
3.9.6. Subcellular fractionation - Nucleus extraction 
 
Nuclear extracts from HT-22 cells were prepared using the nuclear extraction kit 
(Active Motif, Carlsbad, USA) according to the manufacturer’s protocol. For each 
nucleus extract cells from three individual 75 cm2 flasks were pooled, each of them 
containing 1-2x106 cells. Cells were washed once with PBS supplemented with 
phosphatase inhibitors and then collected in fresh buffer (all components supplied 
with the kit). Cells were spinned down at 500 rpm for 5 minutes and resuspended in 
500 µl hypotonic buffer, to which additional 25 µl of detergent were added. Following 
disruption of the cytosolic membrane occurring after 15 minutes of incubation, the 
nuclei were spinned down at 14,000 g for 30 seconds and washed once with 
hypotonic buffer. The nuclei were then incubated in 60 µl complete lysis buffer for 30 
minutes on ice. Samples were vortexed initially and after completing incubation. The 
remaining membrane fraction was removed afterwards by centrifugation at 14,000 g 
for 15 minutes. Samples were analyzed by Western blot analysis as described 
before. 
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3.9.7. Subcellular fractionation - Mitochondrial extraction 
 
Isolation of mitochondria from HT-22 cells was performed by Julia Grohm as 
described previously (144). Briefly, 1x107 cells were harvested for each treatment 
condition and suspended in mito-fractionation buffer (Table 11). Following cellular 
disruption using a glass douncer, nuclei were separated by centrifugation at 830 g for 
10 min. The remaining supernatant was centrifuged again at 16,800 g for 10 minutes 
to seperate the cytosolic fraction. The supernatant was then transferred to another 
tube and the remaining pellet, representing the mitochondrial fraction, was 
resuspended in 50 µl buffer. Mitochondrial extracts were analyzed by Western blot 
analysis following standard procedures. 
 
Table 11: Mitochondrial fractionation buffer, pH 7.5 
Sucrose 4.28 g 
HEPES 0.24 g 
EDTA 0.06 g 
NaOH 0.1M q.s. 
Bidest dH20 add to a final volume of 50 ml 
 
3.10.  PCR 
 
3.10.1.  RNA-Extraction 
 
For RNA extraction HT-22 cells were grown in 24 well plates at an average density of 
60,000 cells/well. RNA extracts were prepared using the Nucleo Spin II Kit 
(Macherey und Nagel, Düren, Germany) according to the manufacturer’s instructions. 
Briefly, HT-22 cells were washed with PBS and harvested in cell lysis buffer R1 
supplemented with 1 % β-Mercaptoethanol.  
For each group, 4-6 wells were pooled to gain appropriate amounts of mRNA. Before 
continuing with the extraction, all samples were shock-frozen in liquid nitrogen and 
left to thaw slowly on ice. Next, the raw extracts were filtered through Nucleospin-
RNA II columns to remove cellular debris. The supernatant was supplemented with 
ethanol, mixed carefully and loaded on a NucleoSpin RNA II column to extract 
nucleic acids by adsorption to the silica matrix of the column.  
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Excessive electrolytes were removed by washing with MDB buffer (supplied with the 
kit). Possible contaminations with genomic DNA were removed by adding 
recombinant DNAse. Further, purification of the column-bound RNA was achieved by 
subsequent purification, using RA2 and RA3 buffers. RNA was eluted in RNAse free 
water supplied with the Nucleo Spin Kit II. RNA-concentration was determined by 
UV-Vis absorption spectroscopy at 260nm. For intermediate storage RNA-extracts 
were transferred to the -80°C freezer. 
3.10.2.  RT-PCR 
 
Following RNA purification, mRNA was amplified using the OneStep PCR kit 
supplied by Invitrogen (Karlsruhe, Germany). Sequence specific primers were used 
for CYLD and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as indicated in 
section 3.3.5. Each sample was prepared according to the following scheme given in 
table 12. 
 
Table 12: ONE STEP PCR sample composition CYLD 
2x reaction buffer 25 µl 
Sample (0.1-1µg) x µl (0.5 µg) 
fw primer (10µM) 1 µl 
rv primer (10µM) 1 µl 
SuperScript III enzyme 2 µl 
Nuclease free water add to a final volume of 50 ml 
 
Table 13: ONE STEP PCR sample composition GAPDH 
2x reaction buffer 12.5 µl 
Sample (0.1-1µg) x µl  
fw primer (5µM) 1 µl 
rv primer (5µM) 1 µl 
SuperScript III enzyme 1 µl 
Nuclease free water add to a final volume of 25 µl 
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For amplification of CYLD and GAPDH the following cycler programs were used. 
 
Table 14: ONE-Step PCR cycler program – murine GAPDH 
60° C 30 min   
95° C 2 min   
95° C 30 sec  
57° C 1 min  
25 cycles 
70° C 2 min  
70° C 10 min 
} 
 
  4° C ∞   
 
Table 15: ONE Step PCR cycler program - murine CYLD 
60° C 30 min   
95° C 2 min  
95° C 15 sec 
55° C 30 sec 
68° C 1 min 
 
25 cycles  
68° C 5 min 
 
 
} 
 
  4° C ∞   
    
3.11. Generation of siRNA using recombinant DICER enzyme 
 
The Dicer siRNA Generation Kit (Genlantis, San Diego, USA) has been used to gain 
siRNA duplexes for targeting murine CYLD. The kit contains recombinant Dicer 
enzyme, which cleaves in vitro a pre-transcribed dsRNA into a pool of siRNA 
fragments that may be used later for gene-repression.  
In a first step, mRNA has been extracted as described before, followed by a reverse 
transcription polymerase chain reaction (rtPCR), transcribing mRNA to cDNA. To this 
end oligo dt15 primers and Moloney Murine Leukemia Virus Reverse Transcriptase 
(M-MLVrv) were used (both from Promega, Madison, USA), as well as dNTP and 
dTT (D,L-dithiotreitol, Sigma-Aldrich, Munich, Germany) according to table 16. In a 
subsequent reaction the target template was synthesized by transcribing ssDNA into 
dsDNA (Table 17). To this end, a target region of 750 bp was selected, which did not 
overlap with the start codon of CYLD. Sequence specific primers had been 
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synthesized before, featuring a 5´ T-7 overhang necessary for later binding to the 
T7SuperScript polymerase. PCR products were purified by ethanol/sodium acetate 
precipitation at -20° C and subsequent re-suspension in 70% ethanol.  
After evaporation of the solvent, the DNA pellet was dissolved in nuclease free water. 
The dsRNA was generated by T7 SuperScript polymerase reaction using the dsDNA 
template gained in the previous PCR-reaction. Recovery of dsRNA products was 
achieved, precipitating the PCR products by adding 30 µl of the supplied LiCl- and 
storage at -20° C for 1h. The precipitate was washed once with cold ethanol (70%) 
and dissolved again in nuclease free water. The concentration of dsRNA was 
determined by UV-light absorbance at 260 nm with each A260 unit corresponding to 
40 µg/ml. siRNA was generated by subsequent digestion of dsRNA strands using 
recombinant Dicer enzyme at 37° C for 12 h. siRNA fragments were analyzed and 
semi-quantitatively assessed by agarose gel electrophoresis and UV-light detection 
using a dilution series of siRNA.  
 
Table 16: RT-PCR using dt15 Primer (gaining sscDNA) 
5x reaction buffer 10 µl  Cycler program C° 
Sample (5µg) x µl   65° C 5 min 
Oligo Primer dT15 (100µM) 2.5 µl  37° C 1 h 
DTT 0,4mM 2.5 µl  95° C 5 min 
dNTPs 10mM 2.5 µl    4° C ∞ 
Nuclease free water add to a final volume of 44 µl   
     
M-MLV rv Transcriptase (50U/µl) 5 µl    
RNAsin (40U/µl) 1 µl    
 
Table 17: CYLD PCR Dicer - hot start, PCR mix and cycler program (gaining ds cDNA) 
10x reaction buffer 5 µl   95° C 2 min   
Sample (mind. 200ng) x µl    70° C hold   
fw primer (10µM) 1 µl  addition of polymerase  
rv primer (10µM) 1 µl   95° C 30 sec 
dNTPs (10mM) 1 µl   58° C 1 min 
MgCl2 (25mM) 3 µl   70° C 2 min 
 
 
30 cycles 
Nuclease free water add to a final 
volume of 45 µl 
  70° C 
  4° C 
10 min 
∞ 
 
} 
 
Thermoprime Plus (0,2 U/µl) 5µl       
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Table 18: T7 reaction (generation of dsRNA) 
T7 reaction buffer 2 µl 
dNTPs Mix 8 µl 
PCR template (ds cDNA) 1µg x µl 
Nuclease free water ad to 20 µl 
T7 enzyme 2 µl 
  
Incubation at 37°C for 2-4h 
 
Tabelle 19: Dicer digestion  
DICER reaction buffer 4 µl 
1 µl ATP (10mM) 1 µl 
MgCl2 (50mM) 0.5 µl 
dsRNA (T7 product) 1 µg x µl 
Nuclease free water 2.5 µl - x 
DICER enzyme 2 µl 
  
Incubation at 37° C for 12-18h 
 
3.11.1. Genotyping of CYLD-/- mice 
 
CYLD knockout mice were a kind gift from Reinhard Faessler, Max Planck Institute of 
Biochemistry, Martinsried, Germany. CYLD knockout mice had been generated by 
inserting a lacZ/neomycin cassette into exon 4, rendering CYLD inactive (Figure 7) 
 
 
Figure 7: Generation of CYLD -/- mice (Massoumi et al., Cell, 2006) 
 
Genotyping of CYLD mice was performed, running two PCR reactions, covering the 
lacz insert and the part of the CYLD sequence, into which the lacz cassette is 
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inserted. DNA was extracted from mouse tails using the tissue DNA extraction kit 
according to the manufacturer´s protocol (Peqlab, Erlangen, Germany). DNA was 
amplified by PCR and fragments were analyzed subsequently by agarose gel 
electrophoresis. Primer sequences (“CYLD exon4” and “lacz”) are provided in 3.3.5. 
The band pattern returned by the agarose gel electrophoresis shows a positive lacZ 
band combined with a negative PCR result for CYLD RNA, indicating a homozygous 
CYLD knockout, and vice versa. If both PCR reactions show detectable bands a 
heterozygous genotype is present. However, due to unstable PCR results, CYLD 
knockdown had to be verified by Western blot analysis in primary neuronal cultures.  
 
Table 20: Thermoprime Plus – PCR reaction for CYLD genotyping 
Thermoprime Plus (0,2 U/µl) 5 µl 
PCR Puffer (10x)   5µl 5 µl 
MgCl2 (25mM)   3µl 3 µl 
dNTPs (10mM)   1µl 1 µl 
Primer (10µM)   1µl 1 µl 
Primer (10µM)   1µl 1 µl 
DNA (200ng)   xµl x µl 
Nuclease free H2O Add to a final volume of 50 µl 
  
Table 21: PCR for lacZ and CYLD (Exon4) 
95°C 180 sec 
95°C 60 (45) sec 
72°C (55°C) 240 (45) sec 
72°C 5 (60) sec 
72°C 600 sec 
35 cycles 
4°C ∞ 
 
 
} 
 
 
3.11.2.  Agarose gel electrophoresis 
 
PCR products were analyzed by agarose gel electrophoresis and subsequent 
detection by SYBR Gold (Invitrogen, Karlsruhe, Germany) an intercalating agent that 
upon DNA binding increases its fluorescent emission. Usually 1.5 g of agarose 
(Sigma-Aldrich, Taufkirchen, Germany) were suspended in 100 ml of 1x 
Tris/Borate/EDTA (TBE) buffer (10x stock, Invitrogen, Karlsruhe, Germany) and 
dissolved by heating up the suspension in a microwave oven. For analysis of siRNA 
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fragments gels containing 2-3 % of agarose were used. Remaining clumps of 
agarose were removed by occasional stiring while heating up the suspension. Once 
the agarose was completely dissolved, 2 µl of SYBR Gold was added, stirred 
carefully and the solution was transferred to the gel cartridge to allow gel formation. 
Thereafter, a comb was inserted in the gel, to generate the pockets needed for later 
sample addition. Samples were loaded using 1 µl of PCR product 5 µl nuclease-free 
water (Sigma-Aldrich, Taufkirchen, Germany) and 2 µl of BJ-sample buffer. Next to 
the samples 4 µl of a pre-prepared 100bp reference marker (Fermentas, St. Leon-
Roth, Germany) were loaded on the gel. Electrophoresis was conducted at 110 V for 
1 h. SYBR Gold stained PCR-products were detected by UV-light excitation and 
fluorescent emission using the Chemidoc Imaging System (Bio-Rad, Munich, 
Germany). Pictures were taken and analyzed using Quantitiy One software (Bio-Rad, 
Munich, Germany). 
3.12.  Measurement of NF-κB activity 
 
NF-κB activity was determined using a luciferase-reporter vector that encodes for 
firefly luciferase under the transcriptional control of a NF-κB response element. Thus, 
upon successful transfection of the reporter plasmid, changes in transcriptional NF-
κB activity become accessible through the amount of luciferase protein generated by 
a certain cell population. Relative changes of luciferase activity are determined by 
measuring the oxidation of luciferin, a substrate of firefly luciferase. Consequently, 
luciferase protein, set free by cellular lysis is incubated with luciferin in the presence 
of ATP-Mg2+ as a cosubstrate, and the amount of light, which is generated by this 
reaction is measured as a readout (83). The reaction is given in figure 8. 
 
 
Figure 8: Luciferin oxidation catalyzed by Firefly Luciferase  
To assess NF-κB activity in HT-22 cells the reporter plasmid was transfected 
following the PEI-transfection protocol given in the respective section. If siRNA 
transfection was required, this was carried out first, as described in section 3.5.1, and 
then, 24 hours later, the transfection of the reporter plasmid was conducted. 
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Following further 24 h of incubation cells were transferred to 96-well plates suitable 
for luminescence-measurement and subjected to the respective treatment regime on 
the following day. Luciferase activity was determined at the indicated time points 
using the luciferase assay system (Promega, Madison, USA) according to standard 
procedures. Briefly, cells were washed with PBS and lysed with passive lysis buffer 
(Promega, Madison, USA). Addition of luciferin substrate and subsequent 
measurement of luciferase activity was achieved using the Fluostar OPTIMA plate 
reader equipped with a luminescense collection lense and an automated injection 
system (BMG Labtech, Offenburg, Germany).  
As an internal control, experiments were repeated in a 24-well layout, to allow for the 
normalization to protein content (when indicated). For evaluation of luciferase activity 
equal amounts of extract were transferred to a chemiluminescence plate, with the 
other half being used for protein determination. 
3.13.  In vivo model of traumatic brain injury 
 
Traumatic brain injury was simulated using a model system of controlled cortical 
impact as described previously (37). CYLD knockout mice and wild-type littermates 
were subjected to controlled cortical impact (CCI) to the surface of the brain 
(impactor tip diameter: 3 mm, impact velocity: 8 m/s, brain compression: 1 mm for 
150 ms). Before CCI animals were craniotomized above the right parietal cortex 
under Halothane/N2O anesthesia.  
Following the controlled impact, the craniotomy was closed again. Sham-operated 
animals underwent the same surgical procedure including anesthesia and craniotomy 
without receiving impact injury. For quantification of brain injury, animals were 
sacrificed by cervical dislocation in deep halothane anesthesia. Brains were carefully 
removed, frozen in dry ice and stored at!-80°C until further use. Histomorphometric 
quantification was performed using 10 µm coronal sections that had been collected 
every 500 µm on a cryostat (CryoStar HM 560, Microm, Walldorf, Germany) and 
stained with cresyl violet. The contusion area of each section was measured on 
digitized images with a standard image analysis software (Optimate 6.52, Media 
Cybernetics, Silver Spring, MD, USA) by an investigator blind to the treatment of the 
animals. The infarct volume (Vi) was calculated based on the contusion areas (A) 
obtained from 15 sections by the equation: Vi = 0.5mm x (A1 + A2 + … + A15) 
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4. Results 
4.1.  Glutamate-dependent cell death in HT-22 cells 
 
HT-22 cells are a well established model for studying the mechanisms underlying 
neuronal cell death induced by oxidative stress (19; 76; 78). Exposing HT-22 cells to 
millimolar concentrations of glutamate results in ROS-dependent cell death (oxytosis) 
caused by glutamate mediated inhibition of the xCT transporter (73; 84). Such 
glutamate-induced cell death occurs in a time dependent manner, usually 8-12 h 
after onset of glutamate exposure and is easily monitored by standard cytotoxicity 
assays like the MTT assay (Figure 9A).  
Oxytosis in HT-22 cells is accompanied by pronounced changes in cellular 
morphology (Figure 9B), which correlate well with overall viability (82). The 
impedance based xCELLigence system has recently been validated as a suitable 
tool for real time monitoring of cell death, exploiting morphological changes for 
readout (82).  
As depicted in figure 9A and 9C, oxytosis in HT-22 cells follows a characteristic 
profile, showing no damage over the early hours of treatment and a sudden, fast 
paced cell death occurring 8-10 hours post glutamate exposure. In line with earlier 
findings, cell death in HT-22 cells occurs as a two-step process, with early events of 
continuously increasing cellular stress like e.g. increases in lipid peroxidation and 
later events such as AIF translocation from mitochondria to the nucleus (76; 78).  
Sensitivity to glutamate varies in HT-22 cells with passage number and cell density, 
for which reason glutamate concentrations were recurrently adapted, using 
concentrations between 1-5 mM for the induction of cell death in the present study. 
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Figure 9: Glutamate induces cell death in HT-22 cells in a time dependent manner. HT-22 cells 
were seeded at a density of 30,000 cells/cm2 and treated with glutamate over the indicated period of 
time. (A) Time dependent cell death in HT-22 cells exposed to glutamate over 6-16h as detected by 
MTT-assay (n=8). (B) HT-22 cells undergoing morphological changes in response to glutamate (10x 
magnification). (C) Cellular impedance recording showing HT-22 cells treated with glutamate as 
recorded by xCELLigence system (n=5). The experiments were repeated three times and the results 
presented as mean values ± S.D. 
 
4.2.  The p53 inhibitor pifithrin-α  prevents glutamate-induced 
oxytosis in HT-22 cells 
 
The tumor suppressor p53 propagates cell death in neurodegenerative diseases, and 
inhibition of p53 is regarded as a promising approach to prevent neuronal loss (28). 
For studying the effects of p53 within neuronal cell death, the p53 inhibitor pifithrin-α 
(PFT) has been established as a valuable and widely applied pharmacological tool 
(85). PFT prevents nuclear translocation of p53 and transcriptional upregulation of 
prominent pro-apoptotic p53 target proteins such as e.g. BAX (86). In order to 
investigate, if p53 was involved in glutamate-induced cell death in HT-22 cells, PFT 
was applied 1 h prior to glutamate treatment. As shown in figure 10A, glutamate-
induced cell death occurs in a concentration dependent manner and could be 
reduced almost completely by the p53-inhibitor PFT (Figure 10A). Such pronounced 
4 Results 
 
49 
protective effect of PFT suggested a significant contribution of p53 to glutamate-
induced oxytosis. 
 
As stated previously, glutamate treatment causes a pronounced increase in reactive 
oxygen species. To address the general concern that PFT functions as a radical 
scavenger, PFT was applied in paradigms of oxidative stress caused by incubation 
with H2O2 or glucose oxidase. While H2O2 poses an imminent burden of ROS, 
addition of glucose oxidase provides a milder source of ROS, inducing a permanent 
but low paced increase in reactive oxygen species. As shown in figure 10B and 10C, 
PFT does not mitigate cell death in response to any of these stimuli, indicating that 
PFT does not possess an anti-oxidative potential and, therefore, does not promote 
neuronal survival by simply acting as a radical scavenger.  
 
Figure 10: PFT protects HT-22 cells against glutamate-induced cell death, but does not act as a radical 
scavenger. HT-22 cells were seeded at a density of 20,500 cells/cm2 in a 96 well plate format. (A) HT-
22 cells were exposed to glutamate (2-4mM) and cell death was determined by MTT assay. Indicated 
groups were pretreated with the p53 inhibitor pifithrin-α (10µM) followed by a co-treatment with 
glutamate (n=8). (B) Cells were exposed to H2O2 (500µM and 1000µM) over 15h, indicated groups 
were co-treated with PFT, starting 1h prior to H2O2. Cell death was detected using the MTT-assay 
(n=8). (C) Treatment of HT-22 cells with glucose oxidase (GO, 10mU/ml and 15mU/ml) causes 
significant cell death after 15h, as determined by MTT-assay. Indicated groups were treated with PFT 
starting 1h prior to GO-treatment (n=8). All experiments were repeated three times and the results 
presented as mean values ± S.D. 
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4.3. The NF-κB pathway is not stimulated by glutamate or pifithrin-α  
 
It is commonly accepted, that p53 induced cell death relies to a great extent on the 
enhanced expression of various pro-apoptotic factors under transcriptional control of 
p53, like BAX, Bid, PUMA and Noxa (29). In addition, a complementary mechanism 
has been identified in tumor cells and neuronal cells that involves concomitant 
repression of NF-κB transcriptional activity by p53 through competitive binding of 
transcriptional cofactors such as p300 and CREB binding protein (CBP) (36; 50). 
Consequently, survival signaling by NF-κB is increasingly impaired in the event of cell 
death, mirrored by decreased levels of anti-apoptotic factors, such as e.g. IAPs and 
MnSOD (33; 37). Following this concept of reciprocal transcriptional inhibition 
between p53 and NF-κB, the present study sought to elucidate how neuroprotection 
induced by inhibition of p53 affected NF-κB activity.  
In contrast to previous work, the present investigation relied on HT-22 cells to 
investigate this question. The HT-22 cells were treated with glutamate and PFT 
(10µM) over different time intervals. Protein levels of IkB-α and pIkB-α were 
determined to estimate induction NF-κB activity along the canonical pathway. 
Activation of this pathway is reflected by initially increased levels of phosphorylated 
IkB-α, followed by IkB-α degradation and subsequent release of the NF-κB 
transcription factors from the inhibitory IkB-complex.  
As shown in figure 11 whole protein extracts were taken from HT-22 cells at the 
indicated time points and analyzed by Western blot for IkB-α and pIkB-α levels. 
Interestingly, neither treatment caused a change in protein levels of IkB-α and pIkB-
α, indicating that the canonical NF-κB pathway was not initiated in the present model 
system.  
 
Figure 11: Glutamate treatment and PFT do not stimulate the canonical NF-κB pathway in HT-22 cells. (A, 
B) HT-22 cells were grown in 6 well plates (21,000 cells/cm2) treated with PFT (10µM) and glutamate 
over the indicated time course. Protein extracts were taken and analyzed by Western blot, probing for 
pIκB-α, IκB-α and Aktin as a loading control. All experiments were repeated three times. 
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Besides the most prominent canonical activation of NF-κB alternative pathways have 
been described, which lead to transcriptional activation of NF-κB without affecting 
pIκB-α and IκB-α levels. To cover these mechanisms as well, a broad approach was 
applied studying the individual role of all NF-κB subunits in response to PFT and 
glutamate.  
As mentioned previously, the transcriptional response by NF-κB can be mediated by 
five isoform subunits, which dimerise upon activation, translocate from the cytoplasm 
to the nucleus and bind to NF-κB response elements for induction of transcription. 
Consequently, the cytosolic/nuclear distribution of any given subunits is a first 
approach for estimating the transcriptional activity.  
In order to investigate the diverse role of the different NF-κB subunits in HT-22 cells, 
all transcription factors were stained, applying immunocytochemistry and analyzed by 
confocal microscopy. Counterstaining of the nuclei with DAPI allowed evaluating 
nuclear translocation.  
HT-22 cells were treated with glutamate and PFT in ibidi-slides and fixed 12 h later 
using PFA. In HT-22 cells, all NF-κB subunits (p50, p52, p65, cRel and RelB) were 
found in the cytosol but not in the nucleus under control conditions (Figure 12). 
Interestingly, no marked translocation of either subunit was detected in the cells 
when stimulated with glutamate or PFT, showing the same distribution pattern as 
control cultures.  
PFT mediated protection against glutamate toxicity was reflected well by unharmed 
cell bodies and nuclei as opposed to shrunken cells and pyknotic nuclei in the 
glutamate-challenged cells. The distribution of NF-κB subunits, however, was 
unchanged in cells protected by PFT compared to controls. These findings clearly 
indicated that the p53 inhibitor PFT could not enhance transcriptional activation of 
NF-κB in HT-22 cells and the associated protective effect was unlikely mediated by 
NF-κB transcriptional activity. 
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Figure 12: NF-κB subunits do not show any sign of nuclear translocation after treatment with 
glutamate or PFT in HT-22 cells (ICC analysis). HT-22 cells were treated with PFT (10µM) and 
glutamate. NF-κB subunits were stained by immunocytochemistry (red) and nuclei were 
counterstained with DAPI (blue). The cytosolic/nuclear distribution pattern of HT-22 cells was not 
markedly altered by PFT or glutamate. 
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To confirm the results gained by immunocytochemistry, the distribution of NF-κB 
subunits was re-evaluated by nuclear/cytosolic fractionation and subsequent Western 
blot analysis. In line with previous findings NF-κB subunits show a predominant 
cytosolic distribution, which was not altered by any treatment, with PFT or without 
glutamate (Figure 13). 
 
Figure 13: No translocation of NF-κB subunits is detectable in HT-22 cells after glutamate or 
PFT treatment (WB analysis). HT-22 cells were treated with glutamate, PFT (10µM) or a combination 
of the two substances. Nuclear and cytosolic fractions were separated and analyzed by Western Blot, 
probing for NF-κB subunits. Purity of nuclear extracts was confirmed by the absence of α-Tubulin. 
Equal loading was verified, comparing Actin levels. NF-κB subunits do not show any sign of nuclear 
translocation in response to PFT or glutamate. The experiment was repeated three times with similar 
results. 
While previous experiments clearly indicated that neither glutamate nor PFT 
treatment induced translocation of NF-κB subunits to the nucleus, this was 
insufficient for concluding that transcriptional activity of NF-κB was not affected by 
either treatment.  
For instance, it has been shown previously that posttranslational phosphorylation of 
the NF-κB subunit p65 enhances transcriptional activity, without the need for a further 
increase in the nuclear fraction of p65. Given the multitude of possible post-
translational modifications, the present study rather sought to study overall 
transcriptional activity, than screening for individual factors and modifications. To this 
end, NF-κB activity was determined using a luciferase-reporter vector that encoded 
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for firefly luciferase under the transcriptional control of a NF-κB response element as 
indicated in figure 14. 
 
 
Figure 14: NF-κB activity in HT-22 cells is not altered by PFT or glutamate treatment. 
HT-22 cells were transfected with a NF-κB reporter plasmid and reseeded in 96-well plates 24h after 
the transfection. Following 8h of PFT (10µM) and glutamate treatment, NF-κB activity was evaluated 
by luminometric detection of luciferase activity. The NF-κB inhibitor BMS was used as a negative 
control. Glutamate and PFT treatment did not affect transcriptional activity. 
 
In summary, these findings suggested that NF-κB did not play a major role in 
glutamate-induced cell death in HT-22 cells. Moreover, the proposed mechanism of 
PFT-mediated neuroprotection, involving NF-κB transcription in addition to p53 
inhibition was apparently not relevant for this model system.  
 
4.4.  Depolarization and fission of mitochondria is prevented by p53 
inhibition 
 
Disturbance of mitochondrial integrity and function recently emerged as an important 
hallmark of neuronal cell death, implicated in various neurodegenerative diseases 
(87; 88). As established previously, mitochondrial fragmentation and subsequent loss 
of metabolic activity also precedes cell death in HT-22 cells (76; 79). In line with 
these findings, glutamate treatment of HT-22 cells was found to cause pronounced 
mitochondrial fission 8-10 h post glutamate exposure, which coincided well with the 
beginning of the execution phase of cell death (Figure 9C and figure 15).  
The work by Tobaben et al. and Grohm et al. gave rise to the concept of “the point of 
no return” according to which neuroprotection in HT-22 cells cannot be reached, 
once mitochondria are damaged. Thus, given the impact of mitochondrial fission on 
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long-term survival, this study investigated the effect of pifithrin-α on mitochondrial 
morphology and function.  
As shown in figure 15, PFT prevented loss of mitochondrial integrity and glutamate-
induced fission in HT-22 cells. A more detailed analysis of mitochondrial morphology 
was conducted, using the classification scheme introduced by Grohm et al. (2010). 
Accordingly, cells were categorized in 3 subgroups, depending on the degree of 
mitochondrial fragmentation.  
Category 1 represents cells containing an intact tubular network of mitochondria as 
usually found under control conditions, whereas categories 2 and 3 indicate an 
increasing number of fragmented mitochondria. Glutamate toxicity caused a shift 
towards category 2 and 3, whereas PFT treatment rescued mitochondrial 
morphology maintaining the tubular structure of mitochondria found under control 
conditions (Figure 15 A und B).  
 
 
Figure 15: PFT prevents glutamate-induced mitochondrial fragmentation in HT-22 cells. 
Mitochondria of HT-22 cells were stained with MitoTracker (green) and treated with glutamate and 
PFT (10µM) for 10-12h. (A) Representative pictures of mitochondrial morphology, showing increased 
fragmentation induced by glutamate. PFT mediated protection preserves mitochondrial morphology, 
found under control conditions (63x magnification). Nuclei were counterstained with DAPI (blue). (B) 
Cells were counted manually and classified into 3 groups depending on the degree of mitochondrial 
fragmentation. Category 1: elongated, tubular like mitochondria; Category 2: intermediate size; 
Category 3: severe mitochondrial fragmentation. 200 cells were counted per condition (n=5), 
***p<0.001 Category 1 and category 2 of the glutamate + PFT group, compared to respective control 
(ANOVA, Scheffé’s). All experiments were repeated three times and the results presented as mean 
values ± S.D. 
 
Mitochondrial membrane potential, as assessed by JC-1 staining, is a further 
indicator of mitochondrial function, correlating with mitochondrial integrity and overall 
viability (79). In HT-22 cells glutamate treatment induces a significant loss of JC-1 
red fluorescence 10-12 h after glutamate exposure, indicating mitochondrial 
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depolarization (Figure 16). Treatment with the p53-inhibitor, however, could potently 
prevent this loss of mitochondrial potential. Moreover, PFT treatment did not only 
rescue the membrane potential, but also enhanced it beyond original control levels. A 
direct effect of PFT at the level of mitochondria thus may account for this effect and 
may contribute to the neuro-protective potential of the p53 inhibitor. 
 
Figure 16: Glutamate-induced depolarization of mitochondria is blocked by pifithrin-α . HT-22 
cells were exposed to glutamate and PFT (10 µM) in the indicated groups. After 10-12h cells were 
incubated with JC-1 (2µM) for analysis of mitochondrial membrane potential. (A) Representative 
fluorescent pictures (40x magnification) showing glutamate-induced loss of red fluorescence (lower 
panel), which indicates mitochondrial depolarization. PFT treatment protects the mitochondrial 
potential shown by the preserved red fluorescence. Comparable cellular uptake of the dye was 
confirmed by evaluation of the green fluorescence. (B) Quantitative FACS analysis of 10,000 
cells/group. The ionophor CCCP was applied to induce a full decrease in red fluorescence thereby 
functioning as a positive control for mitochondrial depolarization. The decrease evoked by glutamate 
was smaller than the effect observed with CCCP. PFT caused a pronounced increase in mitochondrial 
membrane potential in control cells and in cells exposed to glutamate.  
 
4.5. Inhibition of Bcl-2 and Bcl-XL does not attenuate pifithrin-α  
mediated neuroprotection 
 
Bcl-2 and Bcl-XL are well known members of the Bcl-2 protein family with important 
antiapoptotic functions (12). Bcl-XL and Bcl-2 have been shown to prevent cell death 
by antagonizing the effects of BAX, a further member of the Bcl-2 family with a strong 
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pro-apoptotic function. In response to apoptotic stimuli, BAX induces the formation of 
pores within the outer mitochondrial membrane causing the subsequent release of 
apoptotic factors and cell death (89). By forming heterodimers with BAX, both, Bcl-XL 
and Bcl-2 can sequester BAX and thus prevent cell death.  
Since PFT may exert its neuroprotection partially at the level of the mitochondria and 
Bcl-2 and Bcl-XL are the most prominent anti-apoptotic effectors with a mitochondria 
related mode of action, this study investigated if PFT mediated effects are related to 
Bcl-2 proteins (Figure 15 and 16). To this end, the Bcl-2 inhibitor HA-141 (90) and 
ABT-737, an inhibitor of Bcl-2 and Bcl-XL with a preferential binding for Bcl-XL, were 
used (18).  
HT-22 cells were treated with glutamate for 10 h and PFT (10 µM) was applied as 
described previously.  As shown in figure 17A, co-administration of HA-141 (20 µM) 
did not result in any endogenous toxicity, nor did it enhance glutamate-dependent 
cell death. Moreover, PFT mediated protection was not altered by HA-141, indicating, 
that Bcl-2 did not contribute to protection by PFT. Similar results were obtained with 
ABT-737 (10 µM), suggesting that Bcl-XL was dispensable for PFT mediated 
protection (Figure 17 B). 
 
Figure 17: PFT mediated protection is independent of Bcl-2 and Bcl-XL. (A) HT-22 cells (22,500 
cells/cm2) were treated with glutamate, PFT (10µM) and HA141 (20µM) over 15h. Cell viability was 
assessed by MTT assay (n=8). ***p<0.001 (ANOVA, Scheffé’s-test). (B) HT-22 cells (22,500 
cells/cm2) were treated with glutamate, PFT (10µM) and ABT-737 (10µM) over 15h. Cell viability was 
assessed by MTT assay (n=8). ***p<0.001 compared to glutamate and HA-141 treated cells (n=8) 
(ANOVA, Scheffé’s-test). The experiments were repeated three times and the results presented as 
mean ± S.D. 
 
 
 
0
25
50
75
100
125
Control
PFT
Abt-737
Glutamate
Abt-737 + PFT
 ce
ll 
vi
ab
ili
ty
 (%
)
091130 HT22- ABT only PFT.pzf:Normalize of Data 1 graph - Tue Jul 26 15:01:02 2011
***
Abt 737 10!M, PFT 10!M, BID 10!M - HT22
0
20
40
60
80
100
120
Glutamate
Control
PFT
HA-141
PFT + HA-141
n.s.
***
 ce
ll 
vi
ab
ili
ty
 (%
)
23072009 HT22- HA141 PFT only.pzf:Normalize of Data 1 graph - Tue Jul 26 15:46:25 2011
A B
4 Results 
 
58 
4.6. Silencing the deubiquitinase CYLD promotes neuroprotection 
against glutamate toxicity 
 
The tumour suppressor CYLD has been recognized as a major regulative factor 
within the NF-κB pathway (91). As a deubiquitinating enzyme, CYLD affects 
ubiquitination of its various substrates including Nemo, RIP1, TRAF or Bcl-3 (44; 91; 
92; 93; 94-96). Deubiquitination of these components, in turn, has been associated 
with a decrease in NF-κB activity, while loss of CYLD results in increased 
ubiquitination and enhanced transcriptional activity of NF-κB (51).  
Since neuronal cell death can be mitigated by enhancing survival signaling by e.g. 
NF-κB (44; 92; 93), such survival signaling might be obtained by repressing CYLD in 
neurons. In the present study, siRNA mediated gene silencing was applied to 
elucidate whether CYLD plays a major role in neuronal cell death after glutamate 
toxicity.  
CYLD expression in HT-22 cells was successfully repressed by siRNA treatment, as 
assessed by semi-quantitative analysis of CYLD mRNA and protein content (Figure 
18 A and B). Importantly, silencing CYLD preserved HT-22 cell morphology in 
response to glutamate and significantly reduced glutamate dependent cell death in 
HT-22 cells as detected by MTT assay and impedance measurements (Figure 18 C-
E).  
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Figure 18: CYLD siRNA attenuates glutamate toxicity in HT-22 cells. HT-22 cells were transfected 
with CYLD siRNA for 48h and then exposed to glutamate.  (A, B) Successful knockdown of CYLD was 
confirmed by Western Blot analysis and RT-PCR. (C) Glutamate-induced cell death in HT-22 cells is 
accompanied by pronounced morphological changes that were prevented by CYLD siRNA treatment. 
(D) Cell viability was assessed by MTT assay 10h after addition of glutamate, showing a pronounced 
neuroprotective effect of CYLDsiRNA (n=8). ***p< 0.001 compared to glutamate treated control 
(ANOVA, Scheffé´s) (E) Analysis of cellular impedance confirmed the viability data gained by MTT 
assay. Glutamate causes a drastic drop of the cell index, which was prevented in CYLD depleted 
cells. All experiments were repeated three times and results are displayed as mean values ± S.D. 
 
Similar results were obtained, when HT-22 cells were transfected with a pool of 
siRNAs that had been generated using recombinant DICER enzyme.  
Even though cellular tolerance towards this siRNA pool was comparably low, this 
pool of CYLD siRNA offered a significant degree of protection (Figure 19). 
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Figure 19: Neuroprotection through silencing of CYLD using a pool of DICER-generated siRNA. 
HT-22 cells were transfected with siRNA generated by recombinant DICER enzyme and exposed to 
glutamate. Silencing CYLD offered significant protection against glutamate toxicity. CYLD depletion 
was confirmed by Western Blot analysis (data not shown). ***p< 0.001 compared to glutamate treated 
control (ANOVA, Scheffé´s). The experiment was repeated three times and results are displayed as 
mean values ± S.D. 
 
Detection of propidiumiodide- and Annexin-V stained cells by FACS analysis further 
confirmed the protective potential inherent with CYLD repression, showing a strong 
reduction of the late apoptotic and necrotic cell population (Figure 20).  
 
Figure 20: CYLD siRNA attenuates neuronal cell death in HT-22 cells as determined by FACS 
analysis. (A, B) HT-22 cells were transfected with control-siRNA and CYLD siRNA and exposed to 
toxic doses of glutamate. Cell death was quantified by FACS analysis of Annexin-V/propidium iodide 
stained cells. CYLD siRNA treatment exerts a significant neuroprotective effect (n=4, 10,000 
cells/sample). ***p< 0.001 compared to glutamate treated control (ANOVA, Scheffé´s).  
 
In summary, all assays indicate, that glutamate toxicity occurred to a similar degree 
in control siRNA treated cells and untransfected controls, while silencing CYLD by 
both approaches offered significant protection. These results exposed CYLD as a 
novel and promising target for neuroprotective strategies.  
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4.7.  Silencing CYLD promotes neuroprotection independent of NF-
κB 
 
Massoumi et al. recently reported, that loss of functional CYLD causes an elevated 
nuclear translocation of Bcl-3 complexes, which subsequently led to a dramatically 
increased expression of CyclinD1 and enhanced cellproliferation (97).  
To investigate if these factors under CYLD regulation, contributed to neuronal 
survival, sequence specific siRNAs against CyclinD1 and Bcl-3 were applied. As 
shown in figure 21, both gene silencing approaches caused a downregulation of the 
respective target proteins. Silencing either protein, however, did not affect glutamate 
dependent cell death in HT-22 cells (Figure 21 B and C). Consequently, Bcl-3 and 
CyclinD1 were unlikely to be involved in glutamate-induced oxytosis and did not 
account for protection against glutamate toxicity observed in CYLD deficient HT-22 
cells. 
 
Figure 21: CYLD associated factors CyclinD1 and Bcl-3 are not involved in mediating glutamate 
dependent cell death in HT-22 cells. (A, B) CyclinD1 and Bcl-3 were silenced using siRNAs and 
knockdown efficiency was evaluated by Western Blot analysis. (C, D) HT-22 cells depleted of either 
CyclinD1 or Bcl-3 show no protection against glutamate toxicity, as assessed by MTT analysis. All 
experiments were repeated three times with similar results. 
 
As mentioned before CYLD is a well-established regulative protein of the NF-κB 
pathway (94). Although previous results suggested that NF-κB was not primarily 
involved in glutamate dependent cell death in HT-22 cells (Figure 11 and 14), it 
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remained to be clarified, if silencing CYLD affected NF-κB activity. Consequently, the 
present study sought to investigate if enhanced survival signaling through NF-κB 
accounted for the neuroprotection associated with CYLD repression. To this end, 
protein levels of IkB and pIkB-α were determined by Western Blot analysis, revealing 
that siRNA mediated silencing of CYLD did not alter levels of either protein compared 
to control siRNA or non-transfected cells. Treating HT-22 cells with glutamate, 
likewise, did not cause any detectable effect on protein levels of IkB-α and pIkB-α, 
neither in CYLD siRNA treated cells nor in respective controls. TNF-α was employed 
as a positive control stimulating the canonical pathway of NF-κB, as reflected by 
decreased IkB-α and enhanced pIkB-α levels. Furthermore, transcriptional activity of 
NF-κB was evaluated using a luciferase reporter plasmid. While TNF-α caused a 
pronounced increase in transcription, CYLD silencing did not alter NF-κB activity 
compared to control siRNA. In line with previous results, glutamate treatment did not 
affect NF-κB transcriptional activity, neither in control siRNA treated cells nor in cells 
transfected with CYLD siRNA. 
 
Figure 22: Silencing CYLD does not affect NF-κB transcriptional activity. HT-22 cells were 
transfected with control- and CYLD siRNA and exposed to glutamate for 8h as indicated (A) Western 
Blot analysis of IkB-α and p-IkB-α levels revealed no change in CYLD depleted cells, compared to 
controls. TNF-α (100ng/ml, 1h) was applied as a positive control. (B) Luciferase driven NF-κB reporter 
assay showed no increased transcriptional activity in CYLD depleted cells over control. Treatment with 
TNFα (100ng/ml, 8h) was carried out as a positive control (n=6). *** p< 0.001, compared to untreated 
control (ANOVA Scheffé´s). The experiments were repeated three times and the results were 
calculated as mean ± S.D. 
 
In summary, these findings indicate that the observed neuroprotective effects in cells 
deprived of CYLD were not attributed to survival signaling by NF-κB. 
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4.8.  Glutamate dependent oxytosis in shows features of 
necroptosis 
 
Glutamate dependent oxytosis in HT-22 cells has been characterized as a form of 
caspase-independent cell death (19; 78). Recently, another kind of caspase-
independent cell death has been discovered in non-neuronal cells upon activation of 
death receptors by e.g. FASL and TNF-α (63). Interestingly, this form of cell death, 
also termed necroptosis, depends on CYLD activity as an important regulative 
component (63).  
On the basis of the protective effects obtained with CYLD siRNA, we hypothesized 
that caspase-independent cell death in HT-22 cells may share signaling components 
with this newly discovered necrotic cell death pathway. Accordingly, silencing CYLD 
would promote neuronal survival through inhibition of necroptosis. To test this 
hypothesis, we first investigated whether glutamate-induced oxytosis showed 
characteristic features of necrotic cell death. During necroptosis, the kinases RIP1 
and RIP3 form a complex, also termed necrosome, which has been identified as an 
indispensable step for executing necroptotic cell death (98; 99).  
 
In order to investigate the formation of a RIP1/RIP3 necrosome, protein extracts were 
obtained from HT-22 cells at several time points after onset of glutamate exposure. In 
these extracts, RIP1 protein was pulled down by immunoprecipitation and analyzed 
for possible binding partners by Western blot.  
These experiments revealed, that glutamate toxicity in HT-22 cells was associated 
with consecutively increased binding of RIP3 and RIP1 peaking at 12h after the onset 
of glutamate challenge (Figure 23). As quantified by densitometric analysis, 
RIP1/RIP3 complex formation increased in a time dependent manner reaching 
approximately a two-fold increase compared to control levels (Figure 23). 
Comparable pulldown of RIP1 protein was confirmed in the IP-samples and uniform 
protein loading of the full lysates was confirmed, probing the blot with β-Actin 
antibodies. Interestingly, probing the blots with anti-CYLD antibody did not show any 
binding to the necrosome.  
In summary, these findings indicate, that the necroptotic pathway is activated during 
oxytosis in HT-22 cells and thus may contribute to the progression of cell death in 
this paradigm of cell death. 
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Figure 23: RIP1-RIP3 complex formation in response to glutamate. HT-22 cells were treated with 
glutamate over the indicated time course. (A) Immunoprecipitation of RIP1 from 1.25 mg of whole 
protein extracts. Subsequent analysis of co-precipitated proteins shows an increased interaction with 
RIP-3 (uppermost panel). Equal loading was verified by Western blot analysis using whole extracts 
(lower panels). (B) Quantification of the interaction between RIP1 and RIP3 by assessing the ratio of 
RIP3 to (precipitated) RIP1. The ratio is expressed in relation to control levels. **p<0.01 compared to 
control (ANOVA Scheffé´s). The experiments were repeated three times and the results were 
calculated as mean ± S.D. 
 
4.9. Silencing CYLD prevents the necrosome formation in 
glutamate dependent cell death 
 
Previous results show a complex formation of RIP1 and RIP3 in HT-22 cells exposed 
to toxic doses of glutamate, thereby implying a contribution of necroptosis to cellular 
death in this model. Since CYLD was not detected as a part of this complex, it 
remained to be established if CYLD affected necrosome formation. To address this 
question, immunoprecipitation-experiments were carried out using protein extracts 
from control siRNA and CYLD siRNA treated cells, which had been exposed to 
glutamate. As shown in figure 24 A, glutamate stimulated the formation of the RIP1-
RIP3 complex in control siRNA treated cells confirming the previous findings. 
Quantification of signal intensities revealed an approximate 2-fold increase in RIP1-
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RIP3 interaction (Figure 24 B). In contrast, silencing CYLD prevented RIP1-RIP3 
interaction in response to glutamate. 
 
Figure 24: CYLD repression prevents RIP1-RIP3 complex formation in response to glutamate 
toxicity in HT-22 cells. (A) Immunoprecipitation of RIP1 from 1.25 mg of whole protein extracts 
obtained from control and CYLD siRNA transfected cells. Glutamate treatment caused an increased 
co-precipitation of RIP3, as assessed by Western blot analysis (upper panel). Equal loading and 
CYLD knockdown was verified in the maternal extracts. (B) Quantification of the interaction between 
RIP1 and RIP3, assessing the ratio of RIP3 to (precipitated) RIP1. The ratio is expressed in relation to 
control. **p<0.01 compared to control (ANOVA Scheffé´s). The experiments were repeated three 
times and the results were calculated as mean ± S.D. 
 
Overall, these data unveil a role of necroptosis in glutamate-induced cell death in HT-
22 cells and further suggest a strong link between the CYLD siRNA mediated 
protection and the observed inhibition of necrosome formation.  
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4.10.  RIP1 and RIP3 kinases are keyplayers of glutamate dependent 
cell death  
 
Despite intensive research in the past few years the signaling pathways of 
necroptosis remain largely unknown (100). With the discovery of the RIP1-RIP3 
complex, however, a pronecrotic key-event has been discovered, which propagates 
necrotic cell death (98; 99). Intact RIP1 kinase function has been reported to be a 
crucial requirement for the successful formation of the necrosome (98). In this regard, 
the development of necrostatin-1 (NEC1), a small molecule inhibitor of RIP1 kinase 
function was a further milestone in the research of necroptosis (66).  
Consequently, necrostatin-1 is widely used as a valuable tool for assessing the 
contribution of necroptosis to cell death in any given system. When co-administered 
with glutamate, necrostatin-1 was found to attenuate cell death in HT-22 cells, as 
detected by MTT assay and impedance measurement (Figure 25). Interestingly, 
protection offered by necrostatin-1 remained stable over several hours, indicating a 
permanent protection, rather than a transient effect (Figure 25 B). These findings 
strongly suggest, that necroptosis is an inherent process of glutamate dependent cell 
death and shed light on a possible future strategy to induce neuroprotection. 
 
Figure 25: Inhibition of RIP1 kinase by necrostatin-1 attenuates cell death in HT-22 cells. HT-22 
cells were treated with glutamate and necrostatin-1 (30µM) over 10h. (A) Analysis of cell viability by 
MTT assay revealed the neuroprotective effect of necrostatin-1 (n=8). ***p<0.001 compared to 
glutamate treated control (ANOVA Scheffé´s). (B) Cellular impedance measurements showed a 
pronounced decrease in cell index in glutamate treated cells, which was substantially attenuated by 
necrostatin-1. The experiments were repeated three times and the results are presented as mean 
values ± S.D. 
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RIP3 has been suggested, to be of even greater importance for the execution of 
necroptotic cell death, than RIP-1, partly owing to the fact of its exclusive involvement 
in this pathway (100). Using siRNA mediated silencing of RIP3 and RIP1, we sought 
to further elucidate the role of both proteins in glutamate-treated HT-22 cells and tried 
to confirm the results gained with necrostatin-1. As shown in figure 26 A and B siRNA 
treatment successfully repressed the respective RIP kinase, compared to vehicle 
control and control siRNA.  
When exposed to glutamate, RIP1 depleted cells were partially resistant to glutamate 
toxicity, as detected by MTT assay and compared to controls (Figure 26 C). 
Consequently, a similar degree of protection was achieved by silencing RIP1 as by 
inhibition of RIP1 kinase function using necrostatins. Using a pool of sequence 
specific siRNAs for RIP3, a decisive role of RIP3-kinase in glutamate dependent cell 
death became apparent. As determined by MTT assay, RIP3 siRNA significantly 
protected against glutamate toxicity compared to control and control siRNA (Figure 
26). 
 
Figure 26: Repressing RIP1 and RIP3 promotes neuronal survival in HT-22 cells. HT 22 cells 
were transfected with the indicated siRNA targeting RIP1 or RIP3 (40nM) and were treated with 
glutamate over 10h. (A, B) Western Blot analysis revealed a significant decrease in RIP1 and RIP3 
protein-levels in response to the respective siRNA. (C) Assessing cell viability by MTT assay showed 
a significant protection of RIP1 depleted cells against glutamate-induced cell death (n=8).  (D) MTT 
assay analysis of RIP3 siRNA treated cells revealed a significant protection against glutamate 
dependent cell death (n=8). ***p<0.001, compared to glutamate treated control siRNA (ANOVA, 
Scheffé´s). 
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The effect of RIP1 and RIP3 depletion on cell death was studied in further detail by 
targeting heat shock protein 90 (HSP90). The heat shock protein 90 has been closely 
linked to protein stability of RIP1 and RIP3 by functioning as a chaperone protein. In 
line with this notion, loss of HSP90 function has been associated with a subsequent 
decrease in RIP proteins.  
The antibiotic geldanamycin has frequently been used to reduce the ability of HSP90 
to bind its client proteins. Due to inhibition of the ATPase domain of HSP90 by 
geldanamycin, the scaffold function of HSP90 is inversed, causing HSP90 to present 
its client proteins to the proteasome. As a consequence, most HSP90-binding 
proteins are degraded.  
In accordance with these reports, geldanamycin (1 µM) was found to cause a 
pronounced downregulation of RIP1 and RIP3 protein levels when administered to 
HT-22 cells (Figure 27). Of note, protein levels had already significantly decreased as 
early as 8 hours after initiation of geldanamycin treatment. This is particularly 
relevant, as this effect anticipates the execution phase of cell death, which 
approximately starts 8-10 hours post glutamate exposure (Figure 9). As expected, 
HT-22 cells, which were co-treated with geldanamycin and glutamate, were almost 
completely protected against glutamate-induced cell death (Figure 27). These 
findings thus further strengthen the significance of RIP1 and RIP3 in oxytosis in HT-
22 cells.  
 
Figure 27: Inhibition of HSP90 mediates neuroprotection by degradation of RIP1 and RIP3.  
(A) HT-22 cells were exposed to geldanamycin (1µM) for the indicated period of time. Protein levels of 
RIP1 and RIP3 were evaluated by Western Blot analysis, showing a time dependent decrease in both 
RIP proteins. (B) HT-22 cells were treated with geldanamycin (1µM) and co-stimulated with glutamate. 
As assessed by MTT-assay, geldanamycin treatment abolished glutamate toxicity. ***p< 0.001 
compared to control (ANOVA Scheffé´s). The experiments were repeated three times and the results 
are presented as mean values ± S.D. 
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4.11.  cIAPs are dispensable for CYLD siRNA mediated 
neuroprotection 
 
In TNF-α dependent necroptosis the ubiquitination-level of RIP1 has been identified 
as a molecular determinant of cell death (101). While deubiquitinated RIP1 allows 
progression of necroptosis, the ubiquitinated form has been associated with survival 
through stimulation of NF-κB (101). As previously mentioned, the deubiquitinating 
enzyme CYLD propagates necroptosis by specifically removing lysine 63 linked 
ubiquitin residues from RIP1. In contrast, cIAP proteins have been reported to 
function as ubiquitin ligases of RIP1 proteins thus opposing the effect of CYLD (99; 
102). In a model system of TNF-α induced necroptotic cell death, antagonizing cIAPs 
has been shown to enhance necroptotic cell death, an effect attributed to diminished 
RIP1 ubiquitination (102).  
In order to investigate if this paradigm holds true for the model of HT-22 cells, the 
Smac mimetic SM-164 was employed to downregulate cIAP1 and cIAP2 (103). By 
mimicking the physiological impact of Smac/DIABLO release from mitochondria, SM-
164 causes proteasomal degradation of various caspase-inhibiting proteins, including 
cIAP1 and cIAP2.  
Treating HT-22 cells with SM-164 (100nM) resulted in a near complete degradation 
of both cIAP1 and cIAP2, as determined by Western Blot analysis (Figure 28A). 
Interestingly, treating HT-22 cells with Smac mimetics, however, did not affect 
viability under basal conditions and further did not exacerbate glutamate-induced cell 
death (Figure 28B). To test for the proposed competing effects of cIAPs and CYLD, 
SM-164 treatment was combined with CYLD siRNA. Intriguingly, SM-164 did not 
affect neuroprotection induced by repression of CYLD, resulting in a similar degree of 
protection in the presence or absence of SM-164 (Figure 28C).  
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Figure 28: cIAP1 and cIAP2 do not antagonize the neuroprotective potential of CYLD siRNA in 
HT-22 cells. (A) As evaluated by Western Blot analysis using a pan-cIAP antibody, treatment with the 
Smac mimetic SM-164 (100nM) causes a near complete degradation of both cIAP1 and cIAP2. (B) 
MTT analysis reveals, that treatment with SM-164 (100nM) did not affect glutamate dependent cell 
death in HT-22 cells. (C) Loss of cIAPs did not influence CYLD siRNA mediated neuroprotection 
against glutamate toxicity. *** p< 0.001, compared to glutamate treated control, # p > 0.05 (ANOVA´s 
Scheffé). All experiments were repeated three times and results are expressed as mean valus ± S.D. 
 
4.12.  Overexpressing CYLD does not affect cell viability 
 
Next, this study investigated, whether overexpression of CYLD affected cell viability 
per se. Even though CYLD levels were strongly increased in HT-22 cells transfected 
with an overexpression vector, no significant effect on cell viability became evident. 
This observation was independent of co-stimulation with glutamate (Figure 29). 
These findings further question the relevance of the ubiquitination level of RIP1, 
which can be expected to be vastly decreased by the abundantly available 
deubiquitinase CYLD.  
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Figure 29: Overexpressing CYLD does not enhance glutamate toxicity or induce cell death. HT-
22 cells were transfected with a CYLD overexpression vector. (A) mRNA  
and protein levels were strongly increased in cells transfected with the overexpression vector. (B) 
Overexpression of CYLD did not aggravate glutamate toxicity in HT-22 cells. All experiments were 
repeated three times and results are presented as mean values ± S.D. 
 
4.13.  RIP-1 and CYLD are involved in oxytosis, functioning 
upstream of mitochondrial damage 
 
Glutamate-dependent cell death in HT-22 cells has been closely linked to the 
formation of ROS and lipidperoxides, both originating in great parts from 
mitochondrial dysfunction. Since ROS and lipidperoxides further propagate 
mitochondrial damage, while mitochondrial rupture simultaneously boosts either one 
of them, the cytosolic generation of ROS/lipidperoxides and mitochondrial damage 
forms a self-sustaining loop with a devastating outcome on cell survival. (76; 78; 79).  
Similar to oxytosis in HT-22 cells, TNF-α dependent necrosis had been shown to 
involve ROS formation and the generation of lipidperoxides, with both processes 
bearing a link towards mitochondrial dysfunction (104-106).  
In line with previous findings, HT-22 cells showed a pronounced formation of 
lipidperoxides following glutamate stimulation, as detected by BODIPY-assay (Figure 
30 A and B). Inhibiting RIP-1 kinase activity using necrostatin-1 attenuated this 
glutamate-induced increase in lipidperoxidation (Figure 30 A). Further, repressing 
CYLD by siRNA mediated knockdown provided a similar finding, strongly reducing 
the levels of lipidperoxides (Figure 30B). In summary, these data suggest that 
protection exerted by both approaches occurred upstream of the massive increase in 
lipidperoxides, which preceded cellular death.  
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Figure 30: Inhibition of RIP1 and CYLD attenuated lipidperoxidation in HT-22 cells exposed to 
glutamate. Lipidperoxidation was determined in HT-22 cells following 10 h of glutamate exposure 
using BODIPY staining and subsequent FACS analysis. (A) Treating HT-22 cells with necrostatin1 (30 
µM) prevented the glutamate-induced increase in lipidperoxide-levels (n=4, 10,000 cells/sample). (B) 
Silencing CYLD likewise attenuated the formation of lipidperoxides (n=4, 10,000 cells/sample). 
***<0.001 compared to glutamate treated control (ANOVA Scheffé´s). 
 
The pivotal role of mitochondrial integrity for neuronal survival has been reported 
before (76; 78; 79). As extensively studied by Grohm et al. changes in mitochondrial 
morphology occurring e.g. in response to toxic ROS levels, closely correlated with 
loss of mitochondrial ATP-production, membrane depolarization and subsequent 
cellular death (79). Likewise, a role of mitochondria and mitochondrial ROS has been 
implied in TNF-dependent necroptosis. Consequently, the present study investigated 
the influence of CYLD and RIP1 inhibition on mitochondria.  
To this end, fusion and fission processes were quantified using the classification 
scheme introduced by Grohm et al. and described in chapter 4.4. In line with earlier 
findings these investigations confirmed a glutamate dependent increase in 
mitochondrial fragmentation, reflected by a shift of mitochondrial morphology towards 
category 3 (Figure 31).  
Importantly, necrostatin-1 and CYLD siRNA significantly prevented mitochondrial 
fission and preserved the tubular mitochondrial network as found under control 
conditions (Figure 31). These findings indicate, that RIP-1 and CYLD function 
upstream of mitochondria and further suggest, that the attenuated lipidperoxidation 
observed previously, can be attributed at least partially to this effect. 
A B
HT-22 cells Glutamate 5mM 12h - Necrostatin 30!M
0
10
20
30
40
50
Glutamate
Control
Necrostatin
 %
 o
f c
el
ls
 w
ith
 lip
id
pe
ro
xi
da
tio
n
BODIPY Necrostatin2-neue Darstellung.pzf:Normalize of Data 1 graph - Tue Aug 23 14:12:08 2011
***
***
0
25
50
75
100
Control Control siRNA CYLD siRNA
Glutamate
 %
 o
f c
el
ls
 w
ith
 li
pi
dp
er
ox
id
at
io
n
110120 CYLD siRNA BODIPY andere Darstellung.pzf:Data 2 graph - Tue Aug 23 14:25:45 2011
4 Results 
 
73 
 
Figure 31: Inhibition of RIP1 and CYLD preserves mitochondrial morphology. Mitochondria were 
visualized using the mitochondrial dye MitoTracker-red. Morphological changes in response to 
glutamate were assessed and quantified manually using a classification scheme, which subsumes 
fragmented mitochondria in categories 2 and 3, reflecting increasing fission events. Elongated tubular 
mitochondria as found under control conditions were assigned to category 1. (A) Glutamate toxicity 
causes mitochondrial fragmentation (shift towards category 3), which could be prevented by 
necrostatin1 treatment (n=4, 200 cells/sample). (B) CYLD siRNA also protected mitochondrial 
morphology, maintaining a distribution pattern of mitochondrial categories similar to control conditions 
(n=4, 200 cells/sample). (C) Representative pictures of mitochondrial morphology, showing 
fragmented, dot-like mitochondria in glutamate treated groups and tubular mitochondria in cells pre-
treated with CYLD siRNA. ***p<0.001 compared to glutamate treated control (ANOVA, Scheffé´s). 
  
4.14.  RIP1 and RIP3 do not directly interact with mitochondria 
 
As mentioned previously, accumulation of mitochondrial ROS has been suggested as 
a major trigger of TNF-α dependent necroptosis. Some reports described a direct 
interaction of RIP kinases with mitochondrial enzymes involved in energy metabolism 
and deduced from this a causal role of RIP1 and RIP3 in ROS-dependent 
necroptosis (107; 108). Therefore, another aim of this study was to elucidate whether 
the RIP kinases also promote mitochondrial dysfunction through a physical 
interaction. Immunocytochemical stainings of HT-22 cells treated with and without 
glutamate were carried out, staining the respective RIP-proteins and counterstaining 
mitochondria. In contrast to the findings reported by Temkin et al., confocal 
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microscopy revealed no mitochondrial translocation of RIP1-protein in response to 
glutamate toxicity (Figure 32).  
 
Figure 32: Mitochondrial disintegration in response to glutamate is not caused by a direct 
interaction with RIP1. Cellular distribution of RIP1 in HT-22 cells as detected by 
immunocytochemical analysis. RIP1 (green) is localized in the cytosolic compartment under control 
conditions (left panel). Glutamate toxicity (right panel) does not cause a discernible translocation of 
RIP1 to the mitochondria (red). 
 
Similar findings were obtained for RIP3, which likewise did not translocate to the 
mitochondria upon glutamate addition (Figure 33). 
 
Figure 33: Mitochondrial disintegration is not mediated by a direct interaction of RIP3. Cellular 
distribution of RIP3 in HT-22 cells as detected by immunocytochemical analysis. RIP3 (green) shows 
a predominant cytosolic distribution with a fair degree of nuclear staining under control conditions (left 
panel). Glutamate treatment does not change the distribution pattern of RIP3, no translocation of RIP3 
to the mitochondria (red) can be detected (right panel).  
 
 
Control Glutamate
RIP1 MitoTracker
Merge
RIP1 MitoTracker
Merge
RIP1
RIP3
Control Glutamate
RIP3 MitoTracker
Merge
RIP3 MitoTracker
Merge
4 Results 
 
75 
To confirm these data, mitochondrial extracts were obtained from protein lysates 
originating from HT-22 cells treated with or without glutamate. Subsequent detection 
of RIP kinases was performed by gel electrophoresis and Western Blot analysis. 
Mitochondrial extracts were equally loaded as confirmed by COXIV levels. The 
absence of tubulin in mitochondrial extracts was indicative of a high degree of purity 
(Figure 34). In line with the findings obtained from ICC-stainings and subsequent 
confocal microscopy, glutamate treatment did not cause any increase in RIP1 or 
RIP3 kinases in the mitochondrial fraction. A translocation of either RIP protein to the 
mitochondria thus was not detected in the present model of oxytosis.  
 
Figure 34: RIP1 and RIP3 do not accumulate in mitochondrial extracts from HT-22 cells 
exposed to glutamate. Mitochondrial and cytosolic fractions were obtained from whole protein 
extracts of HT-22 cells treated with or without glutamate, by sucrose gradient centrifugation. Purity and 
loading of extracts was evaluated by α-Tubulin and COXIV levels. RIP1 and RIP3 levels were not 
increased in mitochondrial fractions after glutamate addition.  
 
4.15. Necroptotic cell death signaling occurs independent of TNF-
receptor stimulation and caspase activity 
 
Recent reports and comments gave rise to the concern that necroptosis, occurring in 
response to chemically induced cellular stress, may after all result from an 
endogenous secretion of TNF-α by the dying cells. Consequently, TNF-α had to be 
considered a potential underlying source of necroptosis in the present model system 
(68; 109). To investigate the effect of TNF-α stimulation on cell viability in HT-22 
cells, TNF-α was administered to the cells in concentrations ranging from 100-1000 
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ng/ml. As shown in figure 35 A, however, TNF-α did not cause any cytotoxicity. A 
TNF-α sequestering antibody then was used to determine if autocrine secretion of 
TNF-α contributed to glutamate toxicity in HT-22 cells. Importantly, this antibody did 
not affect glutamate-induced cell death in HT-22 cells (Figure 35 B), indicating that 
autocrine secretion of TNF-α was not involved here.  
We next investigated, if TNF-α modulates glutamate-induced necroptosis in HT-22 
cells. To this end, the cytokine was combined with glutamate. This experiment 
showed no additional toxicity in cells co-treated with both compounds. Interestingly, 
TNF-α was found to reduce glutamate dependent cell death, rather than enhancing it, 
which may be attributed to NF-κB activation (Figure 35 C and Figure 22). In 
conclusion, these data strongly suggest, that TNF-α did not contribute to glutamate 
toxicity in HT-22 cells and thus cannot be considered as the trigger of the necroptotic 
response. 
 
Figure 35: Necroptotic cell death in HT-22 cells does not rely on an autocrine secretion of TNF-
α . (A) HT-22 cells were treated with TNF-α at the indicated concentration for 12h. Cell viability was 
assessed by MTT-assay. TNF-α did not exert cytotoxicity. (B) A TNF-α sequestering antibody was 
added to HT-22 cells at a concentration, capable of neutralizing 500 ng/ml of TNF-α. Following 
glutamate exposure for 10h, cell viability was determined by MTT assay (n=8). Autocrine secretion of 
TNF-α is not contributing to glutamate dependent cell death. (C) Exogenous addition of TNF-α did not 
enhance glutamate toxicity in HT-22 cells (n=8). *p<0.05, ***p<0.001 as compared to glutamate 
treated control (ANOVA Scheffé´s). All experiments were repeated three times and results are given 
as mean values ± S.D. 
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A common characteristic of TNF-α dependent necroptosis and glutamate dependent 
cell death is the caspase independent progression and execution of cell death (78; 
98). To confirm this in HT-22 cells, zVAD-fmk a pan-caspase-8 inhibitor was added 
together with glutamate to the cells.  
In line with earlier results this experiment confirmed that cell death in response to 
glutamate progressed unaltered in the presence of the caspase inhibitors, indicating 
that caspases were dispensable for oxytosis in HT-22 cells (Figure 36). This is 
particularly interesting, as the effective inhibition of caspase-8 is a prerequisite for 
necroptosis in various model systems. Consequently, glutamate dependent cell 
death seemingly exhibits this characteristic as a naturally occurring trait. 
 
Figure 36: Glutamate dependent cell death in HT-22 cells is independent of caspase-8. Addition 
of the pan-caspase inhibitor zVAD-fmk (50µM) did not affect glutamate-toxicity as determined by MTT-
assay. The experiment has been repeated three times with similar results. Results are presented as 
mean ± S.D. 
 
4.16. RIP1 but not CYLD mediates glutamate dependent excitotoxic 
cell death in primary neurons 
 
So far, the effect of neuroprotection through silencing of CYLD has been shown only 
in immortalized HT-22 cells, in which glutamate causes detrimental glutathione 
depletion and subsequent accumulation of ROS. This mechanism of cell death, 
however, reflects only partially the physiological situation, disregarding NMDA 
receptor mediated excitotoxicity as a major pathway of neuronal cell death in 
paradigms of acute brain damage (110; 111). To address this issue and expand the 
understanding of CYLD in cell death mediated by excitotoxicity, in vitro experiments 
were conducted using cultured primary cortical neurons obtained from CYLD-/- and 
wild-type mice. It has been shown previously that cell death induced by NMDA 
receptor stimulation can occur via different pathways (112). While apoptosis was 
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reported as the predominating type of cell death in response to low concentrations of 
NMDA-receptor agonists, high concentrations of glutamate or NMDA induced 
necrotic cell death (112).  
Since CYLD has been characterized as a key player in mediating necroptotic cell 
death (a type of necrosis), this study focused on excitotoxic stimuli, likely to induce 
this form of cell death. Consequently, cultured cortical neurons from CYLD-/- and wild-
type mice were exposed to glutamate concentrations of 200 µM in EBSS for 1 h, 
followed by media change to neurobasal medium. Additionally, QVD, a broad range 
caspase inhibitor was used to evaluate the contribution of apoptotic cell death in 
response to glutamate. QVD addition should help to clarify, if CYLD depletion could 
add to neuroprotection induced by caspase inhibition.  
Following glutamate addition cell death was evaluated 20 h later by assessing 
pyknotic nuclei stained with DAPI. As shown in figure 37, glutamate treated cells 
showed a pronounced degree of 75 % of cell death after 20h, which was attenuated 
when co-treated with QVD. CYLD deficient cells however, were not protected against 
glutamate-mediated excitotoxicity and neither showed increased survival, when co-
treated with QVD, as compared to the respective control (Figure 37). Loss of CYLD 
was confirmed by Western blot analysis (Figure 37 B).  
 
Investigating the impact of RIP1 on excitotoxicity, primary cortical rat neurons were 
treated with necrostatin-1 (50 µM) and exposed to glutamate (500 µM, 1 h). 
Following 1 h of glutamate exposure, medium was changed to preconditioned 
Neurobasal medium. In line with earlier reports (113), necrostatin-1 proved protective 
against excitotoxic cell death in primary neurons, maintaining neuronal survival at 
almost control level (Figure 37 C). Representative pictures of pyknotic nuclei are 
shown in figure 37 D. 
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Figure 37: Inhibition of RIP1, but not CYLD protects primary neurons against excitotoxicity. (A) 
Cortical cultures obtained from CYLD-/- mice were not protected against glutamate damage (200µM 
20h) compared to wild-type neurons. Addition of QVD attenuated cell death irrespective of CYLD 
expression. ***p< 0.001 compared to glutamate treated wild-type (ANOVA, Scheffé´s) (B) Loss of 
CYLD was confirmed in CYLD -/- neurons by Western blot analysis. (C) Cultured primary cortical 
neurons were treated with necrostatin1 (50µM) and exposed to glutamate (500µM). Cell death was 
quantified by manual counting of apoptotic nuclei stained with DAPI (blue), necrostatin1 mitigated 
neuronal death (n=4). (D) Representative pictures of pyknotic nuclei of cultured cortical neurons 
treated with necrostatin-1 (50µM) and glutamate (500µM). The nuclei were stained with DAPI. 
 
4.17. Loss of CYLD protects against traumatic brain injury in vivo 
 
Given the limitations inherent with in vitro studies and the promising data on CYLD in 
the model of HT-22 neurons, this study further investigated the protective potential of 
CYLD depletion in an in vivo model of traumatic brain injury. This series of in vivo 
experiments using CYLD-/- mice and wild-type littermates was performed by the 
collaborating group of Nikolaus Plesnila.  
CYLD knockout mice and wild-type littermates were craniotomized above the right 
parietal cortex under Halothane/N2O anesthesia and subjected to controlled cortical 
impact to the surface of the brain. Following the controlled cortical impact, the 
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craniotomy was closed again. CYLD deficient mice showed a significantly reduced 
contusion volume 24 h after controlled cortical impact compared to wild-type mice 
24h post trauma (Figure 38 A). Formation of brain edema, as determined by the dry-
wet weight method was attenuated in CYLD-/- mice compared to wild-type littermates 
(Figure 38 B). Similarly, CYLD knockout mice experienced a lower intracranial 
pressure than their wild-type controls (Figure 38 C).  
 
Figure 38 CYLD deficiency preserved brain tissue following traumatic brain injury. (A) CYLD 
knockout mice and wild-type littermates were subjected to controlled cortical impact to the surface of 
the brain. The contusion area was determined on the basis of digitized images taken from coronal 
sections stained for cresyl violet. CYLD deficient mice showed a significantly reduced contusion 
volume 24h after controlled cortical impact compared to wild-type mice at 24h. p< 0.01 (ANOVA, 
Scheffé´s). (B) Formation of brain edema was determined using the dry-wet weight method 24h after 
traumatic brain injury. CYLD deficient mice demonstrated a significant reduction in brain edema 
formation. *p< 0.05; (Mann-Whitney-U-test) (C) CYLD knockout mice showed a lower intracranial 
pressure compared to wild-type litter-mates. *p< 0.05; (Mann-Whitney-U-test).  
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5. Discussion 
 
The major aim of this study was to explore the roles of p53 and CYLD in neuronal 
cell death and to connect their function herein with the neuronal NF-κB pathway. This 
issue was addressed in immortalized mouse hippocampal HT-22 neurons and in 
primary neuronal cultures exposed to toxic glutamate concentrations. Furthermore, 
an in vivo model system of traumatic brain injury was employed using wild-type and 
CYLD-/- mice.  
The first part of this study revealed a strong neuroprotective effect of p53 inhibition by 
the p53-inhibitor pifithrin-α in HT-22 cells. The obtained data show that the 
disturbance of mitochondrial morphology and mitochondrial membrane potential in 
neuronal cell death was prevented by the p53 inhibitor pifithrin-α. Surprisingly, 
however, the results indicated that neuroprotection induced by pifithrin-α did not 
involve NF-κB activity. Further, NF-κB expression and transcriptional activity were not 
significantly altered in HT-22 neurons that were exposed to glutamate. Based on 
these data, it is concluded that the NF-κB pathway was not significantly involved in 
glutamate-induced oxytosis in this model system.  
 
In the second part, this study investigated the role of CYLD in neuronal cell death in 
vitro, using HT-22 neurons and primary cortical neurons, as well as in vivo using 
C57bl6 mice.  
CYLD function was studied using sequence specific siRNA, revealing a pronounced 
degree of protection in CYLD depleted HT-22 cells. Despite of the established role of 
CYLD as a negative regulator of NF-κB, neuroprotection induced by silencing of 
CYLD was completely independent of NF-κB. These findings are in line with the 
results obtained in the first part of the study, highlighting a minor role of NF-κB in this 
model system.  
Investigating the underlying cause of neuroprotection associated with CYLD 
depletion, this study unveiled that oxytosis in HT-22 cells occurs through 
mechanisms of necroptosis. This conclusion is based on the finding, that complex 
formation of RIP1-RIP3, the so-called necrosome, a hallmark of necroptotic cell 
death, has been found in HT-22 neurons and silencing of either RIP-kinase provided 
strong neuroprotection. In turn, repressing CYLD prevented the formation of the 
necrosome, suggesting that inhibition of necroptosis was the underlying mechanism 
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by which CYLD depletion promoted neuroprotection. The role of necroptosis in 
excitotoxic cell death in primary cortical neurons, as established in this study, 
remains to be clarified. Even though inhibition of RIP1 kinase by necrostatin-1 could 
significantly enhance neuronal survival, CYLD depletion had no effect on cell death in 
this model of excitotoxicity in primary neurons. The physiologically highly relevant in 
vivo model of traumatic brain injury, however, exposed a strong neuroprotection in 
CYLD-/- mice compared to wild-type littermates, rendering CYLD a key player in 
acute neuronal cell death.  
In summary, these data highlight a yet unknown role of CYLD in neuronal cell death 
and unravel the inhibition of necroptosis as a putative therapeutic approach for acute 
and chronic neurodegenerative diseases. 
 
5.1. Neuroprotection by pifithrin-α  – no crosstalk between p53 and 
NF-κB in HT-22 cells 
 
The transcription factor p53 is a prominent tumor suppressor with manifold functions 
in DNA repair, cell cycle arrest and cell death. As p53 is activated upon DNA-
damage, it mediates the following cellular response leading either to DNA repair or 
controlled cell death. For this reason p53 is also referred to as the “guardian of the 
genome” (114). DNA stability, however, is not only of utter importance for tumor 
suppression, it similarly has a great impact on neuronal survival.  
Consequently, activation of neuronal p53 and subsequent cell death has been 
described in response to genotoxic stress, ROS and excitotoxicity in vitro and in 
cerebral ischemia and traumatic brain injury in vivo. These results were confirmed in 
HT-22 neurons, demonstrating a strong neuroprotective effect of the p53 inhibitor 
pifithrin-α in glutamate dependent cell death.  
In the past, complementary mechanisms had been suggested to contribute to 
neuroprotection by pifithrin-α, extending beyond the inhibition of the transcriptional 
upregulation of the pro-apoptotic p53 target proteins like e.g. BAX, PUMA or Noxa 
(36; 37; 115). In line with this notion, p300 had been identified as a crucial co-
transcription factor, inter-connecting the p53 and the NF-κB pathway in primary 
neurons and in vivo (36). It became evident, that both transcriptional pathways 
compete for the same intracellular pool of p300 to induce effective transcription. 
Consequently, p53 inhibition by pifithrin-α was found to increase the pool of freely 
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available p300, thereby enhancing concomitantly the pro-survival pathway NF-κB. In 
HT-22 neurons, however, the present study could not detect an enhanced NF-κB 
response, when p53 was inhibited with pifithrin-α. Thus, a complementary 
mechanism of pifithrin-α that might involve NF-κB seems irrelevant for protective 
effects observed in HT-22 cells.  
A possible explanation for the differing results may lie in the model system employed 
here. Earlier results were obtained in cultured primary hippocampal neurons, which 
undergo excitotoxic cell death in response to glutamate receptor stimulation. 
Furthermore, it has been shown previously that glutamate stimulation can also initiate 
the NF-κB pathway per se in primary neurons (116).  
This stands in sharp contrast to the model system of HT-22 cells employed in this 
study. In HT-22 cells, cell death depends on glutathione depletion but is completely 
independent of ionotropic glutamate receptors (73; 84) and further does not elicit any 
sign of NF-κB response. Taken together, these differences in basal NF-κB response 
and cell death mechanism likely account for the deviating findings on the connection 
between NF-κB and pifithrin-α mediated protection in HT-22 cells, as compared to 
primary cells. 
 
5.2. Mitochondrial p53 is involved in pifithrin-α  mediated 
neuroprotection 
 
As discussed before, this study could not substantiate the reported link between p53 
inhibition and enhanced survival signaling via NF-κB in HT-22 cells. Nonetheless, the 
present study could establish a preliminary line of evidence of a transcription-
independent mechanism, by which inhibition of p53 promoted neuronal survival. In 
particular, data gained on the effect of the p53 inhibitor pifithrin-α at the level of 
mitochondria hint at a direct mechanism occurring at this organelle, which may be 
independent of the nuclear action of p53.  
In this respect, inhibition of p53 by pifithrin-α was found to preserve mitochondrial 
disintegration and inhibit mitochondrial depolarization in response to glutamate 
toxicity in HT-22 cells. Arguably, both observations can also be explained by the 
subsequent effect of pifithrin-α on the BH3 proteins PUMA and Noxa, both under 
transcriptional control by p53. This mechanism, however, could not explain the 
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increase in the mitochondrial membrane potential in response to pifithrin-α, an effect 
most likely mediated directly at the site of mitochondria.  
This notion is further supported by the observation that synaptosomal preparations 
treated with pifithrin-α were protected against mitochondrial depolarisation induced 
by Fe2+ (117). As synaptosomal preparations naturally contain mitochondria, but no 
nucleus, this effect must be mediated independently of p53 transcription. As a simple 
ROS scavenging mode of action of pifithrin-α could be ruled out in this study, a 
separate effect at the level of mitochondria seems most likely, to account for the 
observed protection.  
Interestingly, a possible role of mitochondrial p53 has been reported recently, 
suggesting, that p53 after translocation to mitochondria sequesters the antiapoptotic 
Bcl-2 proteins Bcl-2 and Bcl-XL and thus promotes cell death (118). Although this 
report has been discussed controversially in the field, the finding supports the notion 
of a putative role of mitochondrial p53 in regulating neuronal cell death independently 
of transcriptional activity.  
It is important to note, that neither Bcl-2 nor Bcl-XL were involved in glutamate 
dependent cell death in HT-22 cells, nor in pifithrin-α mediated protection, indicating 
that the role of mitochondrial p53 is different in this model. This conclusion was 
based on the finding, that inhibition of either Bcl-2 family protein did not affect cellular 
survival in the present study.  
A further hint of a direct mitochondrial mechanism of p53 was very recently provided 
by Nijboer et al. who showed that µ-PFT, a small molecule, which inhibits the 
association of p53 with mitochondria without affecting p53 transcriptional activity 
prevents cell death (119).  
In summary, pifithrin-α protected HT-22 neurons by a mechanism, which relied at 
least partially on a direct mitochondrial effect, but was independent of Bcl-2 proteins.  
 
5.3. CYLD is involved in glutamate-induced oxytosis 
 
In the present study the deubiquitinase CYLD has been characterized as an 
important mediator of neuronal cell death in experimental paradigms of oxytosis and 
traumatic brain injury, but not in excitotoxic cell death.  
CYLD originally has been identified as an important negative regulator of NF-κB 
signaling, with loss of CYLD being associated with tumorgenesis and immune 
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dysfunction (94). Within the central nervous system, the role of NF-κB is very 
complex and highly controversial, since numerous reports either designated a pro-
apoptotic or a pro-survival effect to enhanced NF-κB activity.  
The apparent contradiction of these reports has not been completely resolved yet, 
but emerging evidence suggests, that the diverging findings could be explained with 
different experimental settings, different cell types as well as by a NF-κB sub-type 
specific effect (44; 93; 120). In neuronal cultures, NF-κB complexes mostly promote 
survival, whereas in microglial cells and glial-neuronal co-cultures NF-κB stimulation 
has been associated with an increased inflammatory response and an overall 
adverse effect (93).  
Given the alleged effect of sustained NF-κB transcription in neurons, the working-
hypothesis emerged that by depleting CYLD enhanced NF-κB activity could be 
obtained, which then promotes neuronal survival.  
In the present study it was found, that CYLD repression by siRNA in HT-22 neurons 
significantly reduced glutamate dependent cell death as determined by numerous 
detection methods. Surprisingly, however, this study showed that neuroprotection 
through targeted deletion of CYLD in HT-22 cells was independent of NF-κB activity. 
This conclusion is based on the finding, that NF-κB activation and transcriptional 
activity were unaffected by CYLD depletion in HT-22 cells exposed to glutamate 
(Figure 22). These results are especially interesting, when compared to recent 
reports from other groups, which confirmed the reportedly strong correlation between 
NF-κB activity and cellular levels of CYLD (121; 122). In the light of these reports it 
becomes obvious, that the susceptibility to CYLD depletion must be far less 
pronounced in HT-22 cells than in other cells.  
In conclusion, silencing CYLD in HT-22 cells promotes neuroprotection against 
glutamate toxicity by a mechanism, which is independent of NF-κB signaling. 
 
5.4. Neuronal cell death in HT-22 cells occurs by necroptosis and 
can be prevented by CYLD siRNA 
 
With the recent discovery of a controlled signaling network that regulates necrotic cell 
death, Hitomi et al. challenged the long held belief that necrotic cell death always 
occurs in an uncontrolled manner (63). Until then, only apoptosis was regarded as an 
ordered form of cell death involving tightly regulated, highly controlled and 
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interconnected signaling pathways. Necrosis, in contrast, was considered to occur in 
response to nonspecific and unphysiological stress, leading to an unregulated 
cellular rupture (123).  
Though plenty of open questions remain unanswered concerning the precise 
executing mechanisms of necrosis, several key players have been identified (69). In 
addition to CYLD, the complex formation of RIP1 and RIP3, also termed necrosome, 
is considered as a central component in the regulation of necroptosis (63; 100). 
Interestingly, this study found an increasing formation of the necrosome in neuronal 
HT-22 cells exposed to glutamate. Consequently, oxytosis in HT-22 cells cannot be 
regarded as pure apoptosis, but rather a mixed form of cell death, with a prominent 
contribution of necroptosis.  
Repressing CYLD, in turn, prevented cell death and inhibited the formation of the 
necrosome, indicating a regulatory link between these molecular entities. If this 
involved a direct interaction of CYLD with the necrosome, however, remains to be 
established, since we could not detect any physical interaction between CYLD and 
the RIP1-RIP-3 complex.  
 
In TNF-α induced cell death, two distinct cytosolic complexes have been described 
secondary to receptor stimulation and assembly of the multiprotein complex 1 (69).  
One of these complexes is the previously mentioned pro-necrotic necrosome, which 
encompasses next to RIP1 and RIP3 also FADD, TRADD and an inactive caspase-8. 
The second complex consists of FADD, TRADD and an active form of caspase-8, 
which triggers the activation of downstream caspases, thus promoting apoptotic cell 
death. This proapoptotic complex II is stabilized by the active caspase-8, which has 
been shown to cause degradation of both, RIP1 and RIP3 and thereby prevent the 
formation of the alternative pro-necrotic variant of complex II, the necrosome (99; 
124).  
Consequently, complex II promotes either caspase mediated apoptosis or RIP 
mediated necroptosis, depending on the activity of caspase-8.  
The formation of the caspase-dependent pro-apoptotic complex and a possible 
contribution to cell death in HT-22 cells, however, seems very unlikely, as this study 
and earlier reports clearly ruled out any involvement of caspase-8 in oxytosis. In fact, 
no protection could be detected in cells that had been treated with the well-accepted 
pan-caspase inhibitor zVAD-FMK.  
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This data confirms earlier findings by Landshamer et al. who reported similar 
observations with zVAD-fmk and the more specific IETD-fmk, which both failed to 
protect HT-22 cells against oxytosis (78). The same study further demonstrated, that 
caspase-8 activity was not enhanced after glutamate treatment, thereby supporting 
the conclusion that caspase-8 is dispensable for oxytosis (78).  
The mechanism proposed by this thesis, a caspase independent and RIP1/RIP3 
dependent type of cell death is further supported by the finding, that neither RIP1, nor 
RIP3 were markedly degraded during cell death in HT-22 cells. This were to be 
expected according to earlier reports on complex II and caspase-8 dependent cell 
death, if apoptotic signaling predominated (69).  
In summary, these findings suggested that the formation of the necrosome in HT-22 
cells likely contributed to glutamate-induced cell death in a RIP1 and RIP3 dependent 
manner, but occurred independently of caspase-8 function. Further, CYLD siRNA 
was found to prevent RIP1/RIP3 complex formation, thereby promoting survival in 
HT-22 cells. 
 
5.5. Inhibition of RIP1 and RIP3 promotes protection against 
neuronal cell death in HT-22 cells 
 
In addition to the aforementioned keyplayers of necroptosis, like CYLD, RIP1 and 
RIP3, the kinase function of RIP1 has been demonstrated to be of great importance 
for the formation of the necrosome and the inhibition of cell death (98). It has been 
suggested, that reciprocal phosphorylation of RIP1 and RIP3 is the determinant of a 
successful kinase-driven initiation of necroptosis (98).  
With the development of necrostatin-1, a compound became available which 
specifically prevented necroptosis by inhibiting RIP1-kinase (66). Recent reports, 
however, challenge the specificity of this compound for blocking necroptosis, since 
e.g. cIAP induced apoptotic cell death was also prevented with necrostatin-1 (125; 
126). Nevertheless, necrostatin-1 is still considered an important predictive tool for 
evaluating the involvement of necroptosis (69).  
In the present study this compound was successfully used to prevent cell death in 
HT-22 cells, thus supporting the idea of a significant role of necroptosis in this model 
system. In accordance with this notion, repressing RIP1 by siRNA offered a similar 
degree of protection against glutamate toxicity. These findings thus confirm and 
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extend an earlier report, according to which necrostatin-1 protects HT-22 cells in an 
BNIP3-dependent way (Bcl-2/E1B 19kDa-interacting protein 3-like protein) (127). 
The decisive role of RIP3 kinase in necroptotic cell death has been well accepted 
and loss of RIP3 has been found to protect against necroptotic cell death in any 
model system studied until today (128).  
In the system of HT-22 cells, silencing RIP3 by siRNA or inducing its degradation by 
geldanamycin likewise attenuated oxytosis. These findings, thus, establish a line of 
evidence for the actual contribution of RIP1 and RIP3 to glutamate dependent cell 
death in HT-22 cells.  
As outlined before, FADD and TRADD have been identified as further components of 
complex II. The role of these molecular entities for the progression of necrotic cell 
death, however, remains controversial (65; 129). In a recent report Welz et al. (2011) 
found in colonic epithelial cells, that FADD deficiency stimulates necrosis, while the 
presence of FADD within complex II promotes apoptosis, as reported by Kalai et al. 
(2002) (129; 130). These findings thus render FADD a putative regulative factor 
within complex II. Intriguingly though, in a different model system of mouse 
embryonic fibroblasts, FADD has been found as an integral part of the active 
necrosome (98). In the light of these controversial findings it would be interesting to 
decipher the role of FADD in the model system of HT-22 cells and oxytosis. 
  
5.6. The ubiquitination of RIP1 may not be detrimental in HT-22 
cells 
 
Ubiquitination of RIP1 is considered a central regulatory element within the pathways 
of TNF dependent necroptosis and apoptosis (125; 131). In this respect, 
deubiquitination of RIP1 has been highlighted as a prerequisite for the induction of 
apoptotic cell death.  
For necroptotic signaling, however, the role of deubiquitinated RIP1 for the 
progression of cell death has only been established indirectly or deduced from the 
findings gained in studies on apoptosis (100).  
Research within the field has been significantly stimulated by the discovery of Smac-
mimetics, a class of compounds, which mimics the effect of mitochondrial 
Smac/DIABLO on the inhibitor of apoptosis (IAP) family of proteins, causing their 
proteasomal degradation (103). cIAPs recently have been recognized as ubiquitin 
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ligases, causing K63 linked polyubiquitination of their various target proteins, 
including RIP1 (131). Using SMAC-mimetics, Bertrand et al. reported, that by 
depleting cIAPs, RIP1 becomes deubiquitinated and thereby loosens its association 
with the prosurvival transforming growth factor-β-activated kinase 1 (TAK1) (131). As 
a consequence, upon TNFR1 stimulation the deubiquitinated RIP1 was found to 
facilitate the assembly of the pro-death complex II (or DISC), encompassing TRADD, 
Fas associated death protein (FADD) and caspase-8 (131).  
Caspase-8 then triggers apoptosis through the caspase-cascade and simultaneously 
cleaves RIP1 and RIP3 thereby preventing necroptosis.  
In conclusion, these findings render RIP1 deubiquitination a major determinant of 
apoptotic cell death. 
 
Similarly, it was shown that treatment with Smac mimetics, sensitizes L929 cells to 
necroptotic cell death in response to TNF-α (102). This report, unfortunately, could 
not correlate the effect of Smac mimetics with the level of RIP1-ubiquitination, as the 
amount of polyubiquitinated RIP1 fell below the detection level. Most intriguingly, the 
same report unveiled, that loss of cIAPs sensitizes L929-cells to TNF-dependent 
necroptosis, but had no effect on all other necroptotic stimuli investigated, including 
FAD and poly(I:C) (102).  
In summary, it may seem plausible from a mechanistic point of view that 
deubiquitination of RIP1 is a general requirement for necroptosis, but explicit proof is 
pending (69; 123; 128; 132) and the intriguing reports at hand deeply require further 
studies. 
 
For the model system of HT-22 cells, the present study likewise tried to address this 
question and sought to establish the role of ubiquitination of RIP1 for the progression 
of glutamate dependent cell death. To this end, the highly potent Smac-mimetic, SM-
164 was applied to achieve a near total depletion of cIAP1 and cIAP2. Interestingly, 
the loss of these RIP1 ubiquitinating proteins did not have any adverse effect on cell 
viability in HT-22 cells. Further, depletion of both cIAPs did not enhance cell death in 
response to glutamate, a process one may have expected to be facilitated, once the 
prosurvival ubiquitin residues on RIP1 were removed.  
Similar to the report by Vanlangenakker et al. the actual level of ubiquitination of 
RIP1 could not be assessed, as it fell below the detection level. Consequently, it 
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remains elusive if RIP1 deubiquitination is necessary for necroptosis and, further, if 
Smac mimetics affect the ubiquitination level of RIP1 at all. 
To further address the potential link between RIP1- ubiquitination and CYLD, the 
deubiquitinating protein CYLD was overexpressed.  
Similar to the effect of Smac mimetics, this approach should also lead to RIP1 
deubiquitination. Overexpressing CYLD, however, was not toxic to the cells, and 
neither enhanced glutamate toxicity.  
Overexpression of CYLD may not have enhanced glutamate toxicity, since the 
endogeneous levels of CYLD were sufficient for a maximal stimulation of necroptosis, 
which consequently cannot be elevated further by CYLD overexpression.  
 
A possible explanation for the first observation, that cIAP depletion does not facilitate 
glutamate dependent cell death in HT-22 cells could be that the loss of the 
ubiquitinating enzymes cIAP1 and cIAP2 is compensated by a yet unidentified E3-
ligase. A potential candidate is the linear-ubiquitin assembly complex (LUBAC), a 
ubiquitin ligase, which adds linear ubiquitin chains to NEMO and RIP1, thereby 
propagating NF-κB signaling and inhibiting apoptosis (53; 133).  
Another explanation for the absent effect of cIAPs could be that cIAP degradation 
does cause RIP1 deubiquitination, but is not of relevance for the induction nor 
progression of cell death in this model.  
In order to verify this hypothesis, a mutated RIP1 lacking all known endogenous 
ubiquitination sites could be generated and expressed in HT-22 cells, while wild-type 
RIP1 is simultaneously repressed by siRNA.  
This approach could serve to clarify the impact of RIP1 ubiquitination on glutamate 
dependent cell death in HT-22 cells. 
Currently, however, the exact role of RIP1 ubiquitination still remains to be 
established, as well as the regulative link between RIP1 and CYLD. 
 
5.7. ROS- Homeostasis and mitochondrial integrity are preserved 
by inhibiting necroptosis in HT-22 cells 
 
The executing mechanisms of necroptosis remain largely unknown with current data 
pointing at the involvement of lipidperoxidation and the formation of ROS at the level 
of mitochondria (104-106). Interestingly, similar mechanisms have been shown in the 
5 Discussion 
 
91 
past to play a major role in glutamate dependent cell death in HT-22 cells, with 
lipidperoxide-formation starting already in the initial phase and mitochondrial damage 
occurring at mid and late stages.  
To highlight its importance, mitochondrial disintegration has also been referred to as 
the “point of no return” in programmed cell death (76; 79). Ultimately, glutamate-
induced cell death in HT-22 cells is executed in a caspase independent manner by 
AIF (78).  
This study confirmed these earlier findings, showing both increased lipidperoxidation 
and mitochondrial damage in response to glutamate. Importantly, necrostatin-1 or 
CYLD siRNA prevented the increase in lipidperoxidation and rescued mitochondrial 
morphology. These data suggest, that key-events established so far in glutamate 
dependent cell death in HT-22 cells also are pivotal downstream events of the 
necroptotic response in HT-22 cells.  
Based on these findings, it can be concluded, that both apoptotic and necroptotic 
pathways must converge upstream of mitochondria and cell death may ultimately be 
executed in a conserved manner through mechanisms of ROS formation and 
mitochondrial demise.  
In line with that notion, a further molecular entity shared between both pathways is 
the NADPH-oxidase. In TNF mediated necrosis, NADPH-oxidase has been 
recognized as a possible source of ROS in addition to mitochondria (134; 135). In 
HT-22 cells, NADPH likewise seems to be involved in oxytosis, as NADPH inhibitors 
significantly attenuated cell death (143).  
 
Necrosis has long been associated with a decline in ATP levels, which also were 
suggested as a characteristic to differentiate between forms of apoptotic and necrotic 
cell death (4; 136; 137). In line with this perception, another downstream mechanism 
of necroptosis has been shown to involve inhibition of the adenine nucleotide 
translocase (ANT), an integral protein of the inner mitochondrial membrane. Under 
physiological circumstances ANT exchanges mitochondrial ATP with cytosolic ADP. 
Thus, inhibition of ANT will reduce intra-mitochondrial ADP levels causing a 
subsequent depletion of ATP synthesis (108). Interestingly, HT-22 cells have 
previously been shown to similarly exhibit a decline in ATP levels when undergoing 
glutamate dependent cell death (143).  
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A possible link between RIP-proteins and the execution of cell death at the level of 
mitochondria was provided by reports describing a direct physical interaction of RIP1 
and RIP3 with mitochondria (107; 108). The data on the cellular localization of RIP1 
and RIP3 obtained in this study, however, could not confirm these earlier reports. 
Accordingly, both RIP proteins showed a predominant cytosolic distribution with no 
detectable changes after glutamate challenge. Therefore, the link, between the 
activation of necroptosis and mitochondrial demise likely occurs at a different stage 
independent of RIP1-RIP3 translocation to the mitochondria.  
 
5.8. Necroptotic cell death in HT-22 cells follows a novel 
mechanism independent of TNF-receptor signaling 
 
As discussed in previous chapters several lines of evidence support an involvement 
of necroptosis in glutamate dependent cell death in HT-22 cells. Despite the shared 
characteristics of TNF dependent necroptosis and glutamate-induced cell death in 
HT-22 cells, significant differences are apparent between the stimuli by which cell 
death is induced.  
Induction of necroptosis is usually carried out by activation of death receptors by their 
respective ligands including FASL, TNF and Trail-ligand. Importantly, death receptors 
are closely associated with downstream complexes of necroptosis like the 
necrosome (69). This connectivity results in a great homology of receptor related 
proteins shared by the necrosome, which not only contains RIP1 and RIP3 but may 
also contain TRADD and FADD.  
 
In contrast hereto, no glutamate receptor stimulation is involved in glutamate-induced 
cell death in HT-22 cells, which is initiated through glutathione depletion and the 
subsequent accumulation of intracellular ROS (73). Recent reports, however, 
suggested that ROS induced necroptosis involves the secretion and autocrine effects 
of TNF-α. Consequently, TNF-α had to be considered as the initiating cause of 
necroptosis also in the present model system of glutamate-induced oxytosis (68; 
109).  
To address this issue, the current study evaluated the possibility of TNF-α, as the 
trigger of cell death in HT-22 cells that had been exposed to glutamate. The data 
obtained here, using TNF-α and a TNF-α sequestering antibody together with 
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glutamate, suggested that no autocrine stimulation of TNF-α occurs in HT-22 cells. 
Further, even when administered exogenously, TNF-α did not promote cell death, for 
which reason the hypothesis of necroptosis due to an autocrine effect of TNF-α was 
rejected for HT-22 cells.  
Thus, it can be concluded that the necrotic response in HT-22 cells is mediated by 
RIP1 and RIP3, triggered independently of death receptor stimulation by a yet 
unidentified mechanism.  
 
Interestingly, Hitomi et al. found a putative involvement of certain components of the 
glutathione redox machinery, namely Gpx4, in necrosis (63).  
Recently, depletion of Gpx4 was shown to enhance lipidperoxidation and subsequent 
caspase-independent but AIF-dependent neuronal cell death (77). Therefore, Gpx4 
may not only function as a pivotal upstream effector of cell death in neuronal HT-22 
cells, but further initiates necroptosis and thus interconnects both, apoptotic and 
necroptotic pathways in this model.  
Very recently, Tenev et al. identified a cytosolic complex, termed ripoptosome, which 
similarly to complex 2 triggers both, necroptosis and apoptosis (126). This does not 
come as a surprise, since the molecular entities recruited to form this complex are 
very similar to complex 2. The major difference is, however, that the formation of the 
ripoptosome occurs exclusively in the cytosol, independent of receptor stimulation. 
To emphasize this difference, the complex has been designated as ripoptosome.  
 
In conclusion, this report supports the notion, that necroptosis can after all be 
initiated independently of membrane bound death receptors by the formation of a 
cytosolic complex, as observed in HT-22 cells. The ripoptosome, nevertheless, is 
most likely not the underlying cause of the RIP1-RIP3 complex formation in HT-22 
cells, as the formation is confined to cell death in response to SMAC-mimetic 
treatment. (126).  
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5.9. RIP-1, but not CYLD mediates glutamate dependent excitotoxic 
cell death in primary neurons 
 
As most of the presented findings on the detrimental role of RIP proteins and CYLD 
are based exclusively on data gained in HT-22 neurons, the experiments were 
extended to glutamate toxicity in primary cortical neurons.  
In this model system, it is well established that the underlying death program is 
triggered by excitotoxicity and includes mitochondrial damage and AIF release to the 
nucleus (19). 
Using the experimental setup of glutamate-induced cell death in primary cultured 
neurons, this study could extend previous findings which had shown a 
neuroprotective effect of necrostatin-1 in a similar model (113).  
Considering necrostatin-1 an indicator for the involvement of necroptosis, this finding 
suggests that also glutamate-induced cell death in primary neurons cannot be 
regarded as a pure form of apoptotic cell death.  
Since RIP1 knockout mice are not viable and siRNA transfection in primary neuronal 
cells was not efficient, this finding could not be confirmed by gene silencing so far. As 
pharmacological compounds may exert unspecific effects besides modulating their 
major target, caution should be warranted when evaluating the role of RIP1 and 
necroptosis in primary neurons solely on the basis of data obtained from experiments 
using necrostatin (138).  
In sharp contrast to siRNA results in HT-22 cells, cultured primary neurons from 
CYLD-/- did not show any protection against glutamate-induced excitotoxicity 
compared to wild-type controls. Whether this was the case because of a different 
death signaling pathway in primary neurons that renders CYLD function dispensable 
for the execution of excitotoxicity, remains to be clarified. The finding, that CYLD 
depletion offered no protection against excitotoxicity even in the presence of caspase 
inhibitors, however, speaks in favour of this hypothesis.  
Caspase inhibitors had been employed to facilitate the detection of a possibly 
marginal protection in CYLD depleted cells, by repressing apoptosis and shifting the 
death signaling towards necrotic processes. However, no difference in glutamate 
toxicity was detected when CYLD-/- neurons were treated with caspase inhibitors 
compared to wild-type controls, suggesting, that CYLD indeed is not involved in 
death signaling in this model. 
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In summary, these data show a convoluted picture of the involvement of necroptosis 
in primary neurons, with a possible role for RIP1 but not CYLD in excitotoxicity. 
Future studies are required to resolve these controversial findings. Open questions, 
that might be addressed include the possible formation of the necrosome in primary 
cultures and the role of RIP3, for which viable knockout mice have been generated 
(130).  
Additionally, it would be worthwhile investigating, if loss of CYLD protects against cell 
death in response to oxygen-glucose deprivation, representing an in vitro model of 
cerebral ischemia with a mechanism independent of NMDA-receptor stimulation. 
  
5.10.  Loss of CYLD protects against traumatic brain injury in vivo 
 
In vitro research offers a feasible and economic way to decipher cell death signaling 
pathways and to determine putative therapeutic approaches in simplified models of 
neuronal cell death. Whether the findings gained in vitro can be transfered to more 
physiological conditions in vivo is the ultimate challenge of every study.  
Since no inhibitor of CYLD is available until today, the current study used CYLD-/- 
mice in a mouse model system of traumatic brain injury to explore the potential 
therapeutic benefit of this approach.  
Interestingly, CYLD-/- mice showed significantly decreased secondary infarct volume, 
brain edema and intracranial pressure 24h after traumatic brain injury, compared to 
wild-type littermates. This finding highlights the significant protective effect of CYLD 
depletion in a model of acute brain damage.  
As mentioned previously, necrosome formation is an essential indicator of 
necroptotic cell death. For this reason, future research should also evaluate brain 
extracts from CYLD-/- mice and wild-type littermates for signs of necrosome 
formation. Interestingly, Northington et al. found a first hint for an involvement of 
necroptosis in acute brain damage using an in vivo model of neonatal ischemia. In 
this model, Northington et al. detected an increase in necrosome formation 3h and 24 
h after ischemia, which was significantly attenuated, when mice received necrostatin-
1 (139).  
Furthermore, Weltz et al. found in a model of chronic intestinal inflammation, that 
programmed necrosis significantly contributes to cellular demise in colitis of the small 
bowel, which was dependent on RIP3 and CYLD function.  
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In the light of these findings it is tempting to speculate that neuroprotection in CYLD-/- 
mice was mediated by blocking necroptotic cell death, the proof of this hypothesis 
however, will have to be delivered in future studies, which may also embrace the 
recently generated RIP3 knockout mice.  
The role of necroptosis in vivo is subject of ongoing research with only few reports 
available on this topic. The findings reported so far, however, fuel the hope that 
inhibiting necroptosis will evolve as an effective strategy for targeting cell death in a 
variety of diseases, including traumatic brain injury and possibly cerebral ischemia 
(130; 140; 141). 
5.11. Conclusion and outlook 
 
This thesis identified CYLD as a major player in neuronal cell death in vitro and in 
vivo. Despite the prominent role of CYLD in regulating NF-κB signaling, it could be 
excluded that this pathway mediates the neuroprotective effect inherent with CYLD 
depletion in HT-22 cells.  
Instead, inhibition of cell death through silencing CYLD has been linked to the 
kinases RIP1 and RIP3. These two molecular entities promote cellular death 
secondary to the formation of a RIP1-RIP3 complex.  
In fact, CYLD depletion could prevent complex formation of RIP1-RIP3 and strongly 
attenuate cell death, indicating, that CYLD acts upstream of RIP1 and RIP3. Since 
repressing CYLD by siRNA significantly reduced mitochondrial damage, it can be 
concluded, that CYLD dependent signaling must converge with other pathways of 
cell death in HT-22 cells upstream of mitochondria. A direct interaction of 
mitochondria and RIP kinases as the putative downstream effectors of CYLD seems 
unlikely, as neither protein has been found to translocate to this organelle upon 
glutamate toxicity.  
The pro-apoptotic Bcl-2 and BAX protein, however, could possibly constitute this 
molecular link between activation of RIP kinases and the downstream events of cell 
death, since phosphorylation of BAX has been reported to enhance its membrane 
affinity and toxicity (142). Therefore it would be interesting to investigate if RIP 
kinases could potentially trigger BAX translocation by inducing its phosphorylation. 
 
The BH3-only protein Bid, another prominent pro-apoptotic protein is also modified 
by phosphorylation. Contrasting to Bax, however, phosphorylation of Bid at all 
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phosphorylation sites known today, commonly diminishes the pro-apoptotic potential 
(142). So, it is tempting to hypothesize, that Bid may carry additional phosphorylation 
sites still unknown today that promote the pro-apoptotic funcion of this protein.  
For this reason a RIP kinase driven activation of Bid seems a possible, though at this 
point hypothetical link between the established mechanisms of cell death in HT-22 
cells and CYLD dependent signaling.   
Depletion of Gpx4 has been established as an initiating mechanism of neuronal cell 
death through enhanced activation of 12/15 LOX, which subsequently triggers 
downstream effector mechanisms of cell death (77). Interestingly, Gpx4 has also 
been linked to CYLD/RIP kinase dependent cell death by a systems biology 
approach, indicating that a decrease in Gpx4 levels may indeed initiate necroptosis 
(63). 
On the basis of the findings obtained in this study, a model is proposed for CYLD 
mediated cell death signaling, incorporating the established findings and the 
proposed interactions (Figure 39).  
 
 
Figure 39: Proposed model of CYLD signaling in oxytosis. Glutamate dependent inhibition of the 
Xc- transporter causes subsequent glutathione depletion and reduced activity of the glutathione 
peroxidase-4 (GPx4). A fall in GPx4 triggers 12/15 LOX activation, but may also initiate the CYLD 
dependent pathway. CYLD activity leads to RIP1-RIP3 complex formation and mitochondrial damage, 
possibly through a RIP-kinase dependent activation of BAX and Bid. Downstream events involve 
mitochondrial depolarization, release of apoptosis inducing factor (AIF) and DNA damage.
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6. Summary 
 
 
Neuronal cell death causes progressive loss of brain tissue and function after acute 
brain injury and in chronic neurodegenerative diseases. Although the pathological 
features of stroke and brain trauma or Alzheimer’s and Parkinson’s disease differ 
greatly, the underlying neuronal damage shares common molecular and cellular 
mechanisms. Despite extensive research and increasing knowledge on the molecular 
pathology, no efficient therapy has been born from these efforts until today. As a 
promising concept to overcome this plight, it has been suggested to enhance 
endogenous survival signaling pathways like the transcription factor NF-κB and thus 
obtain neuroprotection.  
Increasing neuroprotective NF-κB signaling can be achieved by blocking repressors 
of NF-κB transcriptional activity such as p53 and CYLD.  
Both factors may mediate cell death by mechanisms dependent on and independent 
of NF-ΚB signaling. Therefore, the major aim of this study was to explore the roles of 
p53 and CYLD in neuronal cell death and to connect their detrimental effects with 
NF-κB activity. This issue was addressed in immortalized mouse hippocampal HT-22 
neurons and in primary neuronal cultures exposed to glutamate toxicity. Furthermore, 
an in vivo model system of traumatic brain injury was employed to compare infarct 
development after controlled cortical impact in wild-type and CYLD-/- mice. 
  
The present study revealed that both approaches, inhibiting p53 and CYLD 
successfully preserved mitochondrial integrity and function, and significantly 
attenuated neuronal cell death. Surprisingly, however, the pronounced 
neuroprotective effect of the p53-inhibitor pifithrin-α occurred independently of 
enhanced NF-κB activity in HT-22 cells. In addition, neuroprotection induced by 
silencing of CYLD was completely independent of NF-κB, despite of the previously 
established role of CYLD as a negative regulator of NF-κB in keratinocytes. 
In line with that notion, the NF-κB subunit expression and NF-κB transcriptional 
activity were not significantly altered in HT-22 neurons undergoing glutamate 
dependent cell death.  
In conclusion, these data suggested that the NF-κB pathway was neither significantly 
affected by glutamate dependent cell death, nor did it mediate the neuroprotective 
response of CYLD and p53 inhibition in this model system of glutamate toxicity. 
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Interestingly, inhibiting p53 with pifithrin-α maintained mitochondrial morphology and 
mitochondrial membrane potential in HT-22 cells. This effect occurred independently 
of p53 dependent transcription. 
 
Investigating the underlying cause of neuroprotection associated with CYLD 
depletion, it was unveiled that glutamate-induced oxytosis in HT-22 cells occurred 
through mechanisms of necroptosis. This conclusion is based on the detection of 
RIP1/RIP3 complexes as a hallmark of necroptotic cell death in HT-22 cells exposed 
to glutamate. Further, silencing either RIP-kinase provided strong protection of the 
cells. Repressing CYLD, in turn, prevented the formation of the RIP1/RIP3 
necrosome, suggesting that inhibition of necroptosis was the underlying mechanism 
of neuroprotection after CYLD depletion.  
In contrast, CYLD depletion had no effect on cell death in a model of glutamate 
excitotoxicity in primary cultured neurons, while inhibition of RIP1 kinase by 
necrostatin-1 significantly enhanced neuronal survival. These data suggest a CYLD 
independent but RIP1 dependent mechanism of glutamate toxicity in primary 
neurons, which requires further investigation.  
In vivo, however, using a model of traumatic brain injury, CYLD knockout mice 
showed a significantly reduced infarct size compared to wild-type littermates 
suggesting a potent neuroprotective effect inherent with CYLD repression.  
 
In summary the data from this thesis highlight a yet unknown role of CYLD in 
neuronal cell death and unravel CYLD and p53-dependent mechanisms of cell death 
as a putative therapeutic approach for the treatment of acute and chronic 
neurodegenerative diseases. Future research, however, is warranted to further 
elucidate the exact mechanisms leading to CYLD and RIP-kinase activation in 
neurons and to determine the exact molecular link to mitochondria. 
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7. Zusammenfassung 
 
Der Untergang von funktionsfähigem Hirngewebe durch neuronalen Zelltod stellt eine 
zentrale Ursache für die klinische Manifestation von Spätschäden nach Schädel-Hirn 
Trauma und cerebraler Ischämie dar. Auch die Symptomatik fortgeschrittener 
chronisch neurodegenerativer Erkrankungen, wie der Alzheimer- und 
Parkinsonerkrankung ist auf den Verlust neuronaler Funktionalität zurückzuführen. 
Interessanterweise zeigen die zugrundeliegenden zellulären Mechanismen große 
Gemeinsamkeiten, so dass neuronaler Zelltod in diesen Erkrankungen ungeachtet 
ihrer grundsätzlich verschiedenen Ursachen und Ausprägungen in der Regel nach 
Signalwegen der Apoptose, Nekroptose, oder Autophagie erfolgt.  
Trotz intensiver Forschung ist es bis heute jedoch nicht gelungen das gewachsene 
Verständnis der molekularen Zusammenhänge in die Entwicklung einer effektiven 
neuroprotektiven Strategie zu überführen.  
Ein vielversprechender Ansatz, um diesem Mangel an Therapieoptionen in Zukunft 
zu begegnen, sieht die Verstärkung endogener Signalwege vor, die das zelluläre 
Überleben durch Neutralisierung von toxischen Einflüssen sichern.  
Ein wichtiger Vertreter dieser neuroprotektiven Signalwege ist der NF-κB 
Transkriptionsfaktor. Eine Steigerung der Transkriptionsaktivität von NF-κB kann 
durch Hemmung von p53 und CYLD erzielt werden, zwei wichtigen Proteinen, die 
das zelluläre Überleben nicht nur durch Ihren Einfluss auf NF-κB, sondern auch 
durch weitere Mechanismen beeinflussen können.  
Vor diesem Hintergrund war es ein zentrales Ziel dieser Arbeit die Bedeutung von 
p53 und CYLD im neuronalen Zelltod zu untersuchen und ihre Auswirkung auf den 
neuronalen NF-κB Signalweg zu analysieren.  
Um diese Fragestellung zu bearbeiten, wurden im Rahmen dieser Arbeit eine 
neuronale hippokampale Zelllinie (HT-22 Zellen) wie auch Kulturen von primären 
kortikalen Neuronen eingesetzt. Darüber hinaus fand ein in vivo Modell zum Schädel-
Hirn Trauma Anwendung, um die gewonnenen Erkenntnisse in einem physiologisch 
etablierten Tiermodel der akuten Hirnschädigung zu verifizieren.  
 
Die Ergebnisse dieser Untersuchungen zeigen, dass Inhibition von p53 und CYLD 
neuronalen Zelltod verhindern und mitochondriale Funktionalität erhalten kann. 
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Interessanterweise waren die protektiven Effekte beider Ansätze in HT-22 Zellen 
unabhängig vom NF-κB Transkriptionsfaktor.  
Im Einklang mit diesen Ergebnissen stand die Beobachtung, dass Glutamat-
induzierter Zelltod in HT-22 Zellen keine detektierbare Veränderung des NF-κB 
Transkriptionsweges zeigte. In HT-22 Zellen scheint der NF-κB Transkriptionsfaktor 
daher eine untergeordnete Rolle zu spielen und ist zudem an der Vermittlung der 
neuroprotektiven Wirkung von p53 Inhibition und CYLD Depletion nicht beteiligt.  
Es konnte weiterhin gezeigt werden, dass der schützende Effekt von Pifithrin-α 
vermittelter p53 Hemmung anteilig auf transkriptionsunabhängigen Effekten am 
Mitochondrium beruht.  
Der Mechanismus, der dem neuroprotektiven Effekt der CYLD-Depletion zugrunde 
liegt, konnte ebenfalls identifiziert werden.  
Entgegen dem früheren Verständnis haben jüngere Forschungsergebnisse gezeigt, 
dass Mechanismen des kontrollierten Zelltodes nicht rein apoptotische Vorgänge 
sein müssen. Im Einklang mit diesen Erkenntnissen konnte die vorliegende Arbeit 
das Verständnis über kontrollierte nicht-apoptotische Mechanismen des neuronalen 
Zelltods erweitern und zeigen, dass in HT-22 Neuronen Glutamat induzierter Zelltod 
anteilig nach Signalwegen der Nekroptose erfolgt.  
Die Formierung des Nekrosoms, eines Komplexes aus den beiden RIP-Kinasen 
RIP1 und RIP3, gilt gemeinhin als zentraler Induktions- und zugleich 
Exekutionsmechanismus der Nekroptose. Die Bildung dieses Komplexes konnte 
erstmalig für neuronale Zellen im Glutamat-abhängigem Zelltod nachgewiesen 
werden. Mit Blick auf den neuroprotektiven Effekt der CYLD Depletion konnte ferner 
gezeigt werden, dass der Verlust von CYLD die Bildung des Nekrosoms zu 
unterdrücken vermag.  
Die herausragende Bedeutung der beiden RIP Kinasen im Glutamat-abhängigen 
Zelltod in HT-22 Zellen konnte unter Anwendung von siRNA vermittelter selektiver 
Depletion von RIP1 und RIP3 nachgewiesen werden. Der Verlust von jeweils einer 
der beiden RIP-Kinasen sowie die Inhibition der Kinase-Funktion von RIP1 durch 
Necrostatin1 reduzierten signifikant die Glutamat-induzierte Toxizität und den Verlust 
mitochondrialer Funktionalität.  
 
Im exzitotoxischem Zelltod in primären kortikalen Neuronen konnte die vorliegende 
Arbeit keinen protektiven Effekt durch CYLD Depletion zeigen. Die Hemmung der 
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RIP-1 Kinase durch Necrostatin1 hingegen ermöglichte in Analogie zum Model der 
HT-22 Zellen eine deutliche Reduktion des neuronalen Zelltodes.  
Diese Daten deuten auf einen CYLD unabhängigen, aber RIP1 anhängigen 
Mechanismus hin, der Gegenstand künftiger Forschungsbemühungen sein wird. 
Im Tiermodel zum Schädel Hirn-Trauma konnte die vorliegende Arbeit das protektive 
Potential der kontrollierten Hemmung von CYLD jedoch bestätigen und zeigen, dass 
CYLD defiziente Mäuse ein deutlich reduziertes Infarkt-Volumen und Hirnödem nach 
Schädel-Hirn Trauma aufweisen. 
 
Zusammenfassend konnte in dieser Arbeit erstmalig dargestellt werden, dass 
neuronaler Zelltod in vitro und in vivo durch Depletion von CYLD hemmbar ist. 
Weiterhin konnte im Rahmen dieser Arbeit gezeigt werden, dass der neuroprotektive 
Effekt einer Hemmung von p53 anteilig auf mitochondrialen Prozessen beruht. 
Weitere Forschungsbemühungen sind jedoch erforderlich, um den genauen 
Mechanismus zu identifizieren, der zu einer Aktivierung der CYLD und RIP-
abhängigen Signalwege führt und die Effekte von p53 am Mitochondrium auf 
molekularer Basis erklärt. 
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8. Abbreviations 
 
µ  Micro 
µM  Micrometer 
AD  Alzheimer’s Disease 
ADP  Adenosindiphosphate 
AIF  Apoptosis inducing factor 
AMPA  2-amino-3-(3-hydroxy-5-
methylisoxazol-4-yl)proprionate 
ANOVA  Analysis of variance 
ANT  Adenine nucleotide translocase 
APAF-1  Apoptosis protease-activating  
  factor-1 
Aqua demin.  Demineralized water 
ATM  Ataxia telangiectasia mutated 
ATP  Adenosinetriphosphate 
ATR  ATM-related protein 
BC  before Christ 
BCA  Bicinchoninic acid 
Bcl-2  B-cell lymphoma-2 
BH  Bcl-2 homology 
BNIP-3  Bcl-2/E1B 19kDa-interacting protein 3-
like protein 
BODIPY      4,4-difluoro-5-(4- phenyl-1,3- 
       butadienyl) - 4-bora-3a,4a-diaza-s- 
       indacene-3-undecanoic acid 
bp       base pair 
CAD Caspase-activated deoxyribunuclease 
cIAP1 Cellular inhibitor of apoptosis protein-1 
CBP CREB binding protein 
 
CCCP Carbonyl cyanide 3-
Chlorophenylhydrazone 
CCI Controlled cortical impact 
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CO2 Carbon dioxide 
COX Cyclooxigenase 
CREB Cyclic AMP response element binding 
protein 
CYLD Cylindromatosis 
CYPA Cyclophilin A 
 
Cytc       Cytochrome c 
DAPI       4‟, 6-diamidino-2-phenylindole  
       dihydrochloride 
DISC       Death-inducing signaling complex 
DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethylsulfoxide 
DNA       Desoxyribonucleic acid 
dNTP       Desoxyribonucleosidtriphosphate 
DPI       Diphenyleneiodonium chloride 
Drp-1       Dynamin-related protein 1 
ds       double stranded 
DTT       DL-Dithiothreitol  
DUB       Deubiquitinating 
EBSS       Earl’s balanced salt solution 
EDTA       Ethylenediaminetetraacetic acid 
e.g.       for example (exempli gratia) 
EGTA       Ethylene glycol-bis(2- 
aminoethylether)-N,N,N′,N′-tetraacetic 
       acid 
ER       Endoplasmatic reticulum 
FACS       Fluorescence-activated cell sorting 
FADD       Fas-associated death domain 
FasL       Fas-ligand 
FCS       Fetal calf serum 
FITC       Fluorescein isothiocyanat 
fw       forward 
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GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase 
Gbr2 Growth-factor-receptor-bound-protein 
2 
GFP       Green fluorescent protein 
GLUD1      Glutamate dehydogenase 1 
GLUT       Glutamate 
GO       Glucose oxidase 
GpX 4       Glutathione peroxidase 4 
GSH       Glutathione 
h       hour 
HBSS       Hank’s balanced salt solution 
HCl       Hydrochloric acid 
HEPES 4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid 
H2O2       Hydrogen peroxide 
HRP       Horseradish peroxidase 
HSP       Heat shock protein 
IAP       Inhibitor of apoptosis 
ICAD Inhibitor of caspase-activated 
deoxyribonuclease 
ICC Immunocytochemistry 
IGF Insulin-like growth factor 
IκB-α Inhibitory κB-α 
IKKα Inhibitory κB-α kinase 
IKKβ Inhibitory κB-β kinase 
JC-1 5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethyl- 
benzimidazolylcarbocyanine iodide 
JNK       c-Jun N-terminal kinase 
kDa       Kilo Dalton 
LOX       Lipoxygenase 
LUBAC      Linear-ubiquitin assembly complex 
MEM       Minimum essential medium 
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mM       Millimolar 
MnSOD      Manganese superoxide dismutase 
MOMP      Mitochondrial outer membrane  
       permeabilization 
MPTP 1-methyl-4-phenyl-1,2,3,5-
tetrahydropyridine 
MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-  
  diphenyltetrazolium bromide 
NADPH(oxidase)/NOX Nicotinamide adenine dinucleotide 
phosphate 
NaOH Sodium hydroxide 
NEC1 Necrostatin-1 
NF-κB Nuclear factor-κB 
nm Nanometre 
NMDA  N-methyl-D-aspartic acid 
OGD       Oxygen glucose deprivation 
Omi/HtrA2 High temperature requirement protein 
A2 
PARP       Poly(ADP-ribose) polymerase 
PBS       Phosphate buffered solution 
PCR       Poly chain reaction 
PD        Parkinson’s Disease 
PEI       Polyethylenimine 
PFA       Para formaldehyde 
PFT       Pifithrin-α 
pH       Potentia hydrogenii 
PI       Propidium iodide 
PUMA p53 up-regulated modulator of 
apoptosis 
PVDF       Polyvinylidenfluorid 
RHD       Rel homology domain 
RIP1       Receptor interacting protein 1 
RIP3       Receptor interacting protein 3 
ROS       Reactive oxygen species 
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rpm       Rounds per minute 
rv       reverse 
S.D.       Standard deviation 
SDS       Sodium dodecyl sulfate 
siRNA       small interfering ribonucleic acid 
Smac/DIABLO Second mitochondria - derived 
activator of caspase/direct IAP binding 
protein with low pI 
ss single stranded 
TAK1 Transforming growth factor-β 
activated kinase 1 
TBE Tris/Borate/EDTA 
tBid       Truncated Bid 
TBS       Tris-buffered solution 
TBST       Tris-buffered solution with Tween 20 
TE       Trypsin-EDTA 
TEMED      Tetramethylenethylendiamin 
(Cu/Mn/Zn)-SOD Copper/Manganese/zinc)- superoxide 
dismutase 
TNF-α Tumor necrosis factor α 
TNFR1 Tumor necrosis factor receptor 1 
TPA 12-O-tetradecanoylphorbol-13 acetate 
TRADD Tumor necrosis factor receptor type 1-
associated DEATH domain protein 
TRAF2/5      TNF receptor-associated factor 2/5 
TRAIL Tumor necrosis factor-related 
apoptosis-inducing ligand 
UV ultraviolet 
Vi Infarct volume 
Water demin. Demineralised water 
wt Wild type 
XIAP X-chromosomal linked inhibitors of 
apoptosis 
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